BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-2084. [PMID: 17108342 DOI: 10.1056/nejmoa062276] [Cited by in Crossref: 1432] [Cited by in F6Publishing: 430] [Article Influence: 89.5] [Reference Citation Analysis]
Number Citing Articles
1 Mimura I, Nangaku M. The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol. 2010;6:667-678. [PMID: 20877304 DOI: 10.1038/nrneph.2010.124] [Cited by in Crossref: 177] [Cited by in F6Publishing: 164] [Article Influence: 14.8] [Reference Citation Analysis]
2 van Haalen H, Jackson J, Spinowitz B, Milligan G, Moon R. Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: analysis of multinational real-world data. BMC Nephrol 2020;21:88. [PMID: 32143582 DOI: 10.1186/s12882-020-01746-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
3 Handelman GJ, Levin NW. Iron and anemia in human biology: a review of mechanisms. Heart Fail Rev 2008;13:393-404. [PMID: 18363095 DOI: 10.1007/s10741-008-9086-x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 60] [Article Influence: 5.6] [Reference Citation Analysis]
4 Musio F. Kidney Disease and Anemia in Elderly Patients. Clin Geriatr Med 2019;35:327-37. [PMID: 31230734 DOI: 10.1016/j.cger.2019.03.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Garimella PS, Katz R, Patel KV, Kritchevsky SB, Parikh CR, Ix JH, Fried LF, Newman AB, Shlipak MG, Harris TB, Sarnak MJ; Health ABC Study. Association of Serum Erythropoietin With Cardiovascular Events, Kidney Function Decline, and Mortality: The Health Aging and Body Composition Study. Circ Heart Fail 2016;9:e002124. [PMID: 26721912 DOI: 10.1161/CIRCHEARTFAILURE.115.002124] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
6 Stringer S, Sharma P, Dutton M, Jesky M, Ng K, Kaur O, Chapple I, Dietrich T, Ferro C, Cockwell P. The natural history of, and risk factors for, progressive chronic kidney disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol. BMC Nephrol 2013;14:95. [PMID: 23617441 DOI: 10.1186/1471-2369-14-95] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
7 Agarwal AK. Darbepoetin alfa for anemia in chronic kidney disease. Expert Rev Clin Pharmacol 2008;1:369-79. [PMID: 24422692 DOI: 10.1586/17512433.1.3.369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Petzer V, Theurl I, Weiss G. Established and Emerging Concepts to Treat Imbalances of Iron Homeostasis in Inflammatory Diseases. Pharmaceuticals (Basel) 2018;11:E135. [PMID: 30544952 DOI: 10.3390/ph11040135] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
9 Okumi M, Okabe Y, Unagami K, Kakuta Y, Iizuka J, Takagi T, Shirakawa H, Shimizu T, Omoto K, Ishida H, Nakamura M, Tanabe K; Japan Academic Consortium of Kidney Transplantation (JACK). The interaction between post-transplant anemia and allograft function in kidney transplantation: The Japan Academic Consortium of Kidney Transplantation-II study. Clin Exp Nephrol 2019;23:1066-75. [PMID: 31020441 DOI: 10.1007/s10157-019-01737-2] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Tasanarong A, Duangchana S, Sumransurp S, Homvises B, Satdhabudha O. Prophylaxis with erythropoietin versus placebo reduces acute kidney injury and neutrophil gelatinase-associated lipocalin in patients undergoing cardiac surgery: a randomized, double-blind controlled trial. BMC Nephrol 2013;14:136. [PMID: 23829828 DOI: 10.1186/1471-2369-14-136] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
11 Yap DYH, McMahon LP, Hao CM, Hu N, Okada H, Suzuki Y, Kim SG, Lim SK, Vareesangthip K, Hung CC, Nangaku M; APSN HIF-PHI Recommendation Committee. Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF-PH inhibitors. Nephrology (Carlton) 2021;26:105-18. [PMID: 33222343 DOI: 10.1111/nep.13835] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
12 Hamid T, Prabhu SD. Erythropoietin and ventricular remodelling: a VEGF-dependent neovascularity. Cardiovasc Res 2010;87:6-7. [PMID: 20444988 DOI: 10.1093/cvr/cvq127] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Hamano T, Fujii N, Hayashi T, Yamamoto H, Iseki K, Tsubakihara Y. Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry. Kidney Int Suppl (2011) 2015;5:23-32. [PMID: 26097782 DOI: 10.1038/kisup.2015.6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
14 Gómez-Puerta JA, Waikar SS, Solomon DH, Liu J, Alarcón GS, Winkelmayer WC, Costenbader KH. Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal Disease. J Clin Cell Immunol 2013;4:179. [PMID: 24672742 DOI: 10.4172/2155-9899.1000179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
15 Sumida K, Diskin CD, Molnar MZ, Potukuchi PK, Thomas F, Lu JL, Rhee CM, Streja E, Yamagata K, Kalantar-Zadeh K, Kovesdy CP. Pre-End-Stage Renal Disease Hemoglobin Variability Predicts Post-End-Stage Renal Disease Mortality in Patients Transitioning to Dialysis. Am J Nephrol 2017;46:397-407. [PMID: 29130991 DOI: 10.1159/000484356] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
16 Warady BA, Silverstein DM. Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease. Pediatr Nephrol 2014;29:1493-505. [PMID: 24005791 DOI: 10.1007/s00467-013-2557-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
17 Koury MJ, Haase VH. Anaemia in kidney disease: harnessing hypoxia responses for therapy. Nat Rev Nephrol 2015;11:394-410. [PMID: 26055355 DOI: 10.1038/nrneph.2015.82] [Cited by in Crossref: 124] [Cited by in F6Publishing: 121] [Article Influence: 17.7] [Reference Citation Analysis]
18 Inrig JK, Sapp S, Barnhart H, Patel UD, Reddan D, Singh A, Califf RM, Szczech L. Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR. Nephrol Dial Transplant 2012;27:3606-14. [PMID: 22573238 DOI: 10.1093/ndt/gfs123] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
19 Locatelli F, Mazzaferro S, Yee J. Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients. Clin J Am Soc Nephrol 2016;11:1269-80. [PMID: 27185524 DOI: 10.2215/CJN.00080116] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
20 de Vries JK, Levin A, Loud F, Adler A, Mayer G, Pena MJ. Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives. Diabetes Obes Metab 2018;20 Suppl 3:24-9. [PMID: 30294955 DOI: 10.1111/dom.13412] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
21 Seliger SL, Zhang AD, Weir MR, Walker L, Hsu VD, Parsa A, Diamantidis CJ, Fink JC. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int 2011;80:288-94. [PMID: 21389972 DOI: 10.1038/ki.2011.49] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
22 Raichoudhury R, Spinowitz BS. Treatment of anemia in difficult-to-manage patients with chronic kidney disease. Kidney Int Suppl (2011) 2021;11:26-34. [PMID: 33777493 DOI: 10.1016/j.kisu.2020.12.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Gilbertson DT, Peng Y, Arneson TJ, Dunning S, Collins AJ. Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics. BMC Nephrol 2013;14:44. [PMID: 23425362 DOI: 10.1186/1471-2369-14-44] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
24 Salgado Filho N, Lages JS, Brito DJA, Santos EJF, Dos Santos AM, de Souza FL, Mendes VGG, Silva GADS, Carneiro ECRL, Muniz MPR, Silva GEB, Sesso RCC. Variability in Hemoglobin Levels and the Factors Associated with Mortality in Hemodialysis Patients: A 78-Month Follow-Up Study. Int J Environ Res Public Health 2021;18:1078. [PMID: 33530448 DOI: 10.3390/ijerph18031078] [Reference Citation Analysis]
25 Cizman B, Smith HT, Camejo RR, Casillas L, Dhillon H, Mu F, Wu E, Xie J, Zuckerman P, Coyne D. Clinical and Economic Outcomes of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Post-Bundling Era. Kidney Med 2020;2:589-599.e1. [PMID: 33089137 DOI: 10.1016/j.xkme.2020.06.008] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Kilar CR, Sekharan S, Sautina L, Diao Y, Keinan S, Shen Y, Bungert J, Mohandas R, Segal MS. Computational design and experimental characterization of a novel β-common receptor inhibitory peptide. Peptides 2018;104:1-6. [PMID: 29635062 DOI: 10.1016/j.peptides.2018.04.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Nangaku M, Hamano T, Akizawa T, Tsubakihara Y, Nagai R, Okuda N, Kurata K, Nagakubo T, Jones NP, Endo Y, Cobitz AR. Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial. Am J Nephrol 2021;52:26-35. [PMID: 33561857 DOI: 10.1159/000513103] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
28 Maurer MS, Teruya S, Chakraborty B, Helmke S, Mancini D. Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: single-blind randomized clinical trial of safety and efficacy. Circ Heart Fail 2013;6:254-63. [PMID: 23258574 DOI: 10.1161/CIRCHEARTFAILURE.112.969717] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
29 Allon M. Evidence-based cardiology in hemodialysis patients. J Am Soc Nephrol 2013;24:1934-43. [PMID: 24136920 DOI: 10.1681/ASN.2013060632] [Cited by in Crossref: 32] [Cited by in F6Publishing: 7] [Article Influence: 3.6] [Reference Citation Analysis]
30 Meadowcroft AM, Cizman B, Holdstock L, Biswas N, Johnson BM, Jones D, Nossuli AK, Lepore JJ, Aarup M, Cobitz AR. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis. Clin Kidney J 2019;12:139-48. [PMID: 30746141 DOI: 10.1093/ckj/sfy014] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 10.0] [Reference Citation Analysis]
31 Karaboyas A, Morgenstern H, Waechter S, Fleischer NL, Vanholder R, Jacobson SH, Sood MM, Schaubel DE, Inaba M, Pisoni RL, Robinson BM. Low hemoglobin at hemodialysis initiation: an international study of anemia management and mortality in the early dialysis period. Clin Kidney J 2020;13:425-33. [PMID: 32699623 DOI: 10.1093/ckj/sfz065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
32 Eisenga MF, Emans ME, van der Putten K, Cramer MJ, Diepenbroek A, Velthuis BK, Doevendans PA, Verhaar MC, Joles JA, Bakker SJL, Nolte IM, Braam B, Gaillard CAJM. Epoetin Beta and C-Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease. J Am Heart Assoc 2019;8:e011130. [PMID: 31423921 DOI: 10.1161/JAHA.118.011130] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
33 Kovesdy CP, Kalantar-Zadeh K. Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease. Nephrology (Carlton) 2009;14:408-15. [PMID: 19563383 DOI: 10.1111/j.1440-1797.2009.01119.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
34 Huang JY, Hsu CW, Yang CW, Hung CC, Huang WH. Role of anuria in the relationship between indoxyl sulfate and anemia in peritoneal dialysis patients. Ther Clin Risk Manag 2016;12:1797-803. [PMID: 27932887 DOI: 10.2147/TCRM.S120012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
35 Vu K, Zhou J, Everhart A, Desai N, Herrin J, Jena AB, Ross JS, Shah ND, Karaca-Mandic P. Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial. BMC Nephrol 2021;22:284. [PMID: 34419007 DOI: 10.1186/s12882-021-02491-y] [Reference Citation Analysis]
36 Coyle M, Flaherty G, Jennings C. A critical review of chronic kidney disease as a risk factor for coronary artery disease. Int J Cardiol Heart Vasc 2021;35:100822. [PMID: 34179334 DOI: 10.1016/j.ijcha.2021.100822] [Reference Citation Analysis]
37 Thorp ML, Smith DH, Johnson ES, Weiss JW, Vupputuri S, Petrik AF, Yang XH. Should measuring haemoglobin among chronic kidney disease patients be a performance measure? J Evid Based Med 2012;5:194-204. [PMID: 23557499 DOI: 10.1111/jebm.12005] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Wong MMY, Tu C, Li Y, Perlman RL, Pecoits-Filho R, Lopes AA, Narita I, Reichel H, Port FK, Sukul N, Stengel B, Robinson BM, Massy ZA, Pisoni RL; CKDopps Investigators . Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated. Clin Kidney J 2020;13:613-24. [PMID: 32905241 DOI: 10.1093/ckj/sfz091] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 8.3] [Reference Citation Analysis]
39 Bhandari S. Beyond efficacy and safety-the need for convenient and cost-effective iron therapy in health care. NDT Plus 2011;4:i14-9. [PMID: 27045221 DOI: 10.1093/ndtplus/sfr044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
40 Lu JL, Molnar MZ, Sumida K, Diskin CD, Streja E, Siddiqui OA, Kalantar-Zadeh K, Kovesdy CP. Association of the frequency of pre-end-stage renal disease medical care with post-end-stage renal disease mortality and hospitalization. Nephrol Dial Transplant 2018;33:789-95. [PMID: 29106625 DOI: 10.1093/ndt/gfx192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
41 Dore DD, Swaminathan S, Gutman R, Trivedi AN, Mor V. Different analyses estimate different parameters of the effect of erythropoietin stimulating agents on survival in end stage renal disease: a comparison of payment policy analysis, instrumental variables, and multiple imputation of potential outcomes. J Clin Epidemiol 2013;66:S42-50. [PMID: 23849152 DOI: 10.1016/j.jclinepi.2013.02.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
42 Collino M, Benetti E, Rogazzo M, Chiazza F, Mastrocola R, Nigro D, Cutrin JC, Aragno M, Fantozzi R, Minetto MA, Thiemermann C. A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice. Br J Pharmacol 2014;171:5802-15. [PMID: 25164531 DOI: 10.1111/bph.12888] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
43 Beduschi MG, Mello AL, VON-Mühlen B, Franzon O. THE PANC 3 SCORE PREDICTING SEVERITY OF ACUTE PANCREATITIS. Arq Bras Cir Dig 2016;29:5-8. [PMID: 27120730 DOI: 10.1590/0102-6720201600010002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
44 Tsujita M, Kosugi T, Goto N, Futamura K, Nishihira M, Okada M, Hiramitsu T, Narumi S, Uchida K, Takeda A, Morozumi K, Maruyama S, Watarai Y. The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial. Nephrol Dial Transplant 2019;34:1409-16. [PMID: 30561729 DOI: 10.1093/ndt/gfy365] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
45 Dispenzieri A. Complications of myeloma therapy. Hematol Oncol Clin North Am 2007;21:1247-73, xi. [PMID: 17996597 DOI: 10.1016/j.hoc.2007.08.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
46 Foley RN. Target hemoglobin trials in chronic kidney disease: design and interpretation issues. Pediatr Nephrol 2009;24:2279-85. [PMID: 19221807 DOI: 10.1007/s00467-009-1123-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
47 Teehan G, Benz RL. An update on the controversies in anemia management in chronic kidney disease: lessons learned and lost. Anemia 2011;2011:623673. [PMID: 21541213 DOI: 10.1155/2011/623673] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
48 Macdougall IC, Akizawa T, Berns JS, Bernhardt T, Krueger T. Effects of Molidustat in the Treatment of Anemia in CKD. Clin J Am Soc Nephrol 2019;14:28-39. [PMID: 30559105 DOI: 10.2215/CJN.02510218] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 9.5] [Reference Citation Analysis]
49 van der Zee S, Baber U, Elmariah S, Winston J, Fuster V. Cardiovascular risk factors in patients with chronic kidney disease. Nat Rev Cardiol 2009;6:580-9. [PMID: 19621012 DOI: 10.1038/nrcardio.2009.121] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
50 Gobin J, Cernii A, McLean R, Finkelstein FO, Simon DB. Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study. Clin Drug Investig 2011;31:113-20. [PMID: 21067252 DOI: 10.1007/BF03256938] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
51 Mikhail A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, Isaac H, Bhandari S. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol 2017;18:345. [PMID: 29191165 DOI: 10.1186/s12882-017-0688-1] [Cited by in Crossref: 80] [Cited by in F6Publishing: 59] [Article Influence: 16.0] [Reference Citation Analysis]
52 Von Kohorn I, Ehrenkranz RA. Anemia in the preterm infant: erythropoietin versus erythrocyte transfusion--it‘s not that simple. Clin Perinatol. 2009;36:111-123. [PMID: 19161869 DOI: 10.1016/j.clp.09.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
53 Bennett CL, Becker PS, Kraut EH, Samaras AT, West DP. Intersecting guidelines: administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer. Semin Dial. 2009;22:1-4. [PMID: 19175532 DOI: 10.1111/j.1525-139x.2008.00524.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
54 Sun P, Kumar N, Tin A, Zhao J, Brown MR, Lin Z, Yang ML, Zheng Q, Jia J, Bielak LF, Yu B, Boerwinkle E, Hunker KL, Coresh J, Chen YE, Huo Y, Kardia SLR, Khoriaty R, Zhou X, Morrison AC, Zhang Y, Ganesh SK. Epidemiologic and Genetic Associations of Erythropoietin With Blood Pressure, Hypertension, and Coronary Artery Disease. Hypertension 2021;78:1555-66. [PMID: 34488438 DOI: 10.1161/HYPERTENSIONAHA.121.17597] [Reference Citation Analysis]
55 Noguchi CT, Wang L, Rogers HM, Teng R, Jia Y. Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med 2008;10:e36. [PMID: 19040789 DOI: 10.1017/S1462399408000860] [Cited by in Crossref: 77] [Cited by in F6Publishing: 49] [Article Influence: 5.5] [Reference Citation Analysis]
56 Roger SD, Tio M, Park HC, Choong HL, Goh B, Cushway TR, Stevens V, Macdougall IC. Intravenous iron and erythropoiesis-stimulating agents in haemodialysis: A systematic review and meta-analysis. Nephrology (Carlton) 2017;22:969-76. [PMID: 27699922 DOI: 10.1111/nep.12940] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
57 Mendelssohn DC, McFarlane P. Conditionally funded field evaluations--a solution to the economic barriers limiting evidence generation in dialysis? Semin Dial 2011;24:556-9. [PMID: 21906167 DOI: 10.1111/j.1525-139X.2011.00970.x] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
58 Zhang Y, Thamer M, Kaufman JS, Cotter DJ, Hernán MA. High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. Kidney Int 2011;80:663-9. [PMID: 21697811 DOI: 10.1038/ki.2011.188] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
59 Kato S, Takahashi T, Miyata N, Roman RJ. DMOG, a Prolyl Hydroxylase Inhibitor, Increases Hemoglobin Levels without Exacerbating Hypertension and Renal Injury in Salt-Sensitive Hypertensive Rats. J Pharmacol Exp Ther 2020;372:166-74. [PMID: 31801803 DOI: 10.1124/jpet.119.262782] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
60 Kilar CR, Diao Y, Sautina L, Sekharan S, Keinan S, Carpino B, Conrad KP, Mohandas R, Segal MS. Activation of the β-common receptor by erythropoietin impairs acetylcholine-mediated vasodilation in mouse mesenteric arterioles. Physiol Rep 2018;6:e13751. [PMID: 29939494 DOI: 10.14814/phy2.13751] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
61 Metra M, Nodari S, Bordonali T, Bugatti S, Fontanella B, Lombardi C, Saporetti A, Verzura G, Danesi R, Dei Cas L. Anemia and heart failure: a cause of progression or only a consequence? Heart Int 2007;3:1. [PMID: 21977269 DOI: 10.4081/hi.2007.1] [Reference Citation Analysis]
62 Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL, Aiello JR, Novak JE, Lee T, Leong R, Roberts BK, Saikali KG, Hemmerich S, Szczech LA, Yu KH, Neff TB. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD. Clin J Am Soc Nephrol. 2016;11:982-991. [PMID: 27094610 DOI: 10.2215/cjn.06890615] [Cited by in Crossref: 163] [Cited by in F6Publishing: 81] [Article Influence: 27.2] [Reference Citation Analysis]
63 Kalantar-Zadeh K, Lee GH, Miller JE, Streja E, Jing J, Robertson JA, Kovesdy CP. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients. Am J Kidney Dis 2009;53:823-34. [PMID: 19339087 DOI: 10.1053/j.ajkd.2008.12.040] [Cited by in Crossref: 109] [Cited by in F6Publishing: 98] [Article Influence: 8.4] [Reference Citation Analysis]
64 Lo WK. Latest Strategy in Renal Anemia Management in Peritoneal Dialysis Patients. Perit Dial Int 2008;28:76-80. [DOI: 10.1177/089686080802803s16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Foley RN, Curtis BM, Parfrey PS. Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. Clin J Am Soc Nephrol 2009;4:726-33. [PMID: 19339412 DOI: 10.2215/CJN.04950908] [Cited by in Crossref: 45] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
66 Winterberg PD, Jiang R, Maxwell JT, Wang B, Wagner MB. Myocardial dysfunction occurs prior to changes in ventricular geometry in mice with chronic kidney disease (CKD). Physiol Rep 2016;4:e12732. [PMID: 26997631 DOI: 10.14814/phy2.12732] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
67 Suttorp MM, Hoekstra T, Rotmans JI, Ott I, Mittelman M, Krediet RT, Dekker FW. Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients. BMC Nephrol 2013;14:200. [PMID: 24066978 DOI: 10.1186/1471-2369-14-200] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
68 Ahmed A, Campbell RC. Epidemiology of chronic kidney disease in heart failure. Heart Fail Clin 2008;4:387-99. [PMID: 18760751 DOI: 10.1016/j.hfc.2008.03.008] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 4.0] [Reference Citation Analysis]
69 Khan I, Krishnan M, Kothawala A, Ashfaq A. Association of dialysis facility-level hemoglobin measurement and erythropoiesis-stimulating agent dose adjustment frequencies with dialysis facility-level hemoglobin variation: a retrospective analysis. BMC Nephrol 2011;12:22. [PMID: 21595975 DOI: 10.1186/1471-2369-12-22] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
70 Kaplan JM, Sharma N, Dikdan S. Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease. Int J Mol Sci 2018;19:E389. [PMID: 29382128 DOI: 10.3390/ijms19020389] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
71 Winkelmayer WC, Walther CP. Roxadustat for CKD Anemia - Starting the Jigsaw Puzzle, What Will the Finished Picture Show? Kidney Int Rep 2021;6:559-61. [PMID: 33735328 DOI: 10.1016/j.ekir.2021.01.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
72 Akizawa T, Nangaku M, Yamaguchi T, Arai M, Koretomo R, Matsui A, Hirakata H. A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial. Am J Nephrol 2019;49:165-74. [PMID: 30699415 DOI: 10.1159/000496929] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
73 Braam B, Joles JA, Danishwar AH, Gaillard CA. Cardiorenal syndrome--current understanding and future perspectives. Nat Rev Nephrol 2014;10:48-55. [PMID: 24247284 DOI: 10.1038/nrneph.2013.250] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 8.7] [Reference Citation Analysis]
74 Canney M, Birks P, Shao S, Parfrey P, Djurdjev O, Levin A. Temporal Trends in Hemoglobin, Use of Erythropoiesis Stimulating Agents, and Major Clinical Outcomes in Incident Dialysis Patients in Canada. Kidney Int Rep 2021;6:1130-40. [PMID: 33912762 DOI: 10.1016/j.ekir.2020.12.022] [Reference Citation Analysis]
75 Robles NR. The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease. Clin Drug Investig 2016;36:421-31. [PMID: 26894799 DOI: 10.1007/s40261-016-0378-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
76 Dounousi E, Bouba I, Spoto B, Pappas K, Tripepi G, Georgiou I, Tselepis A, Elisaf M, Tsakiris D, Zoccali C, Siamopoulos K. A Genetic Biomarker of Oxidative Stress, the Paraoxonase-1 Q192R Gene Variant, Associates with Cardiomyopathy in CKD: A Longitudinal Study. Oxid Med Cell Longev 2016;2016:1507270. [PMID: 27313824 DOI: 10.1155/2016/1507270] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
77 Foley RN. Treatment of anemia in chronic kidney disease: known, unknown, and both. J Blood Med 2011;2:103-12. [PMID: 22287869 DOI: 10.2147/JBM.S13066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
78 Yabu JM, Anderson MW, Kim D, Bradbury BD, Lou CD, Petersen J, Rossert J, Chertow GM, Tyan DB. Sensitization from transfusion in patients awaiting primary kidney transplant. Nephrol Dial Transplant 2013;28:2908-18. [PMID: 24009295 DOI: 10.1093/ndt/gft362] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
79 Costa NA, Kshirsagar AV, Wang L, Detwiler RK, Brookhart MA. Pretransplantation erythropoiesis-stimulating agent hyporesponsiveness is associated with increased kidney allograft failure and mortality. Transplantation 2013;96:807-13. [PMID: 23982339 DOI: 10.1097/TP.0b013e3182a0f668] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]
80 Shah R, Agarwal AK. Anemia associated with chronic heart failure: current concepts. Clin Interv Aging 2013;8:111-22. [PMID: 23403618 DOI: 10.2147/CIA.S27105] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
81 Sato Y, Fujimoto S, Konta T, Iseki K, Moriyama T, Yamagata K, Tsuruya K, Narita I, Kondo M, Kasahara M, Shibagaki Y, Asahi K, Watanabe T. Anemia as a risk factor for all-cause mortality: obscure synergic effect of chronic kidney disease. Clin Exp Nephrol 2018;22:388-94. [PMID: 28815319 DOI: 10.1007/s10157-017-1468-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
82 Toto R, Petersen J, Berns JS, Lewis EF, Tran Q, Weir MR. A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD. J Am Soc Nephrol 2021;32:469-78. [PMID: 33288629 DOI: 10.1681/ASN.2020050556] [Reference Citation Analysis]
83 Zarychanski R, Houston DS. Anemia of chronic disease: a harmful disorder or an adaptive, beneficial response? CMAJ 2008;179:333-7. [PMID: 18695181 DOI: 10.1503/cmaj.071131] [Cited by in Crossref: 83] [Cited by in F6Publishing: 65] [Article Influence: 5.9] [Reference Citation Analysis]
84 Galle JC, Addison J, Suranyi MG, Claes K, Di Giulio S, Guerin A, Herlitz H, Kiss I, Farouk M, Manamley N, Wirnsberger G, Winearls C. Outcomes in patients with chronic kidney disease not on dialysis receiving extended dosing regimens of darbepoetin alfa: long-term results of the EXTEND observational cohort study. Nephrol Dial Transplant 2016;31:2073-85. [PMID: 27190334 DOI: 10.1093/ndt/gfw047] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
85 Tannor EK, Norman BR, Adusei KK, Sarfo FS, Davids MR, Bedu-Addo G. Quality of life among patients with moderate to advanced chronic kidney disease in Ghana - a single centre study. BMC Nephrol 2019;20:122. [PMID: 30961570 DOI: 10.1186/s12882-019-1316-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
86 Norouzi S, Zhao B, Awan A, Winkelmayer WC, Ho V, Erickson KF. Bundled Payment Reform and Dialysis Facility Closures in ESKD. J Am Soc Nephrol 2020;31:579-90. [PMID: 32019784 DOI: 10.1681/ASN.2019060575] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
87 Zhang Y, Young JG, Thamer M, Hernán MA. Comparing the Effectiveness of Dynamic Treatment Strategies Using Electronic Health Records: An Application of the Parametric g-Formula to Anemia Management Strategies. Health Serv Res 2018;53:1900-18. [PMID: 28560811 DOI: 10.1111/1475-6773.12718] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
88 Keithi-Reddy SR, Singh AK. Hemoglobin target in chronic kidney disease: a pediatric perspective. Pediatr Nephrol 2009;24:431-4. [PMID: 18604563 DOI: 10.1007/s00467-008-0902-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
89 Chertow GM, Liu J, Monda KL, Gilbertson DT, Brookhart MA, Beaubrun AC, Winkelmayer WC, Pollock A, Herzog CA, Ashfaq A, Sturmer T, Rothman KJ, Bradbury BD, Collins AJ. Epoetin Alfa and Outcomes in Dialysis amid Regulatory and Payment Reform. J Am Soc Nephrol 2016;27:3129-38. [PMID: 26917691 DOI: 10.1681/ASN.2015111232] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
90 Ahmed AT, Go AS, Warton EM, Parker MM, Karter AJ. Ethnic differences in anemia among patients with diabetes mellitus: the Diabetes Study of Northern California (DISTANCE). Am J Hematol 2010;85:57-61. [PMID: 20029942 DOI: 10.1002/ajh.21577] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 0.4] [Reference Citation Analysis]
91 Miller JL, Church TJ, Leonoudakis D, Lariosa-Willingham K, Frigon NL, Tettenborn CS, Spencer JR, Punnonen J. Discovery and Characterization of Nonpeptidyl Agonists of the Tissue-Protective Erythropoietin Receptor. Mol Pharmacol 2015;88:357-67. [PMID: 26018904 DOI: 10.1124/mol.115.098400] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
92 Hahn D, Esezobor CI, Elserafy N, Webster AC, Hodson EM. Short-acting erythropoiesis-stimulating agents for anaemia in predialysis patients. Cochrane Database Syst Rev 2017;1:CD011690. [PMID: 28066881 DOI: 10.1002/14651858.CD011690.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
93 Inrig JK, Bryskin SK, Patel UD, Arcasoy M, Szczech LA. Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors. BMC Nephrol 2011;12:67. [PMID: 22152013 DOI: 10.1186/1471-2369-12-67] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
94 Garikapati K, Goh D, Khanna S, Echampati K. Uraemic Cardiomyopathy: A Review of Current Literature. Clin Med Insights Cardiol 2021;15:1179546821998347. [PMID: 33707979 DOI: 10.1177/1179546821998347] [Reference Citation Analysis]
95 Newsome BB, Onufrak SJ, Warnock DG, McClellan WM. Exploration of anaemia as a progression factor in African Americans with cardiovascular disease. Nephrol Dial Transplant 2009;24:3404-11. [PMID: 19703835 DOI: 10.1093/ndt/gfp304] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
96 Hansen RA, Chin H, Blalock S, Joy MS. Predialysis chronic kidney disease: evaluation of quality of life in clinic patients receiving comprehensive anemia care. Res Social Adm Pharm 2009;5:143-53. [PMID: 19524862 DOI: 10.1016/j.sapharm.2008.06.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
97 Fell LH, Zawada AM, Rogacev KS, Seiler S, Fliser D, Heine GH. Distinct immunologic effects of different intravenous iron preparations on monocytes. Nephrol Dial Transplant 2014;29:809-22. [PMID: 24523357 DOI: 10.1093/ndt/gft524] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
98 Turenne MN, Cope EL, Porenta S, Mukhopadhyay P, Fuller DS, Pearson JM, Dahlerus C, Lantz B, Tentori F, Robinson BM. Has dialysis payment reform led to initial racial disparities in anemia and mineral metabolism management? J Am Soc Nephrol 2015;26:754-64. [PMID: 25300289 DOI: 10.1681/ASN.2013111232] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.9] [Reference Citation Analysis]
99 Kwon O, Jang HM, Jung HY, Kim YS, Kang SW, Yang CW, Kim NH, Choi JY, Cho JH, Kim CD, Kim YL, Park SH; Clinical Research Center for End-Stage Renal Disease (CRC- ESRD) Investigators. The Korean Clinical Research Center for End-Stage Renal Disease Study Validates the Association of Hemoglobin and Erythropoiesis-Stimulating Agent Dose with Mortality in Hemodialysis Patients. PLoS One 2015;10:e0140241. [PMID: 26452232 DOI: 10.1371/journal.pone.0140241] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
100 Noonan ML, Clinkenbeard EL, Ni P, Swallow EA, Tippen SP, Agoro R, Allen MR, White KE. Erythropoietin and a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHDi) lowers FGF23 in a model of chronic kidney disease (CKD). Physiol Rep 2020;8:e14434. [PMID: 32476270 DOI: 10.14814/phy2.14434] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
101 Gobin J, Cernii A, McLean R, Finkelstein FO, Simon DB. Conversion from epoetin alfa to darbepoetin alfa for management of anaemia in a community chronic kidney disease centre: a retrospective cohort study. Clin Drug Investig 2011;31:113-20. [PMID: 21067252 DOI: 10.1007/BF03256938] [Reference Citation Analysis]
102 Fishbane S, El-Shahawy MA, Pecoits-Filho R, Van BP, Houser MT, Frison L, Little DJ, Guzman NJ, Pergola PE. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study. J Am Soc Nephrol 2021;32:737-55. [PMID: 33568383 DOI: 10.1681/ASN.2020081150] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 15.0] [Reference Citation Analysis]
103 Schmidt RJ, Dalton CL. Treating anemia of chronic kidney disease in the primary care setting: cardiovascular outcomes and management recommendations. Osteopath Med Prim Care 2007;1:14. [PMID: 17910755 DOI: 10.1186/1750-4732-1-14] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
104 Sebestyén MG, Hegge JO, Noble MA, Lewis DL, Herweijer H, Wolff JA. Progress toward a nonviral gene therapy protocol for the treatment of anemia. Hum Gene Ther 2007;18:269-85. [PMID: 17376007 DOI: 10.1089/hum.2006.186] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
105 Coyne DW, Singh HN, Smith WT, Giuseppi AC, Connarn JN, Sherman ML, Dellanna F, Malluche HH, Hruska KA. Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification. Kidney Int Rep 2019;4:1585-97. [PMID: 31891000 DOI: 10.1016/j.ekir.2019.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
106 Thomas A, Peterson LE. Reduction of costs for anemia-management drugs associated with the use of ferric citrate. Int J Nephrol Renovasc Dis 2014;7:191-201. [PMID: 24899820 DOI: 10.2147/IJNRD.S65158] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
107 Xu Y, Peng H, Ke B. α-klotho and anemia in patients with chronic kidney disease patients: A new perspective. Exp Ther Med 2017;14:5691-5. [PMID: 29250136 DOI: 10.3892/etm.2017.5287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
108 . Chapter 5: Referral to specialists and models of care. Kidney Int Suppl (2011) 2013;3:112-9. [PMID: 25599001 DOI: 10.1038/kisup.2012.68] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
109 Roger SD. Practical considerations for iron therapy in the management of anaemia in patients with chronic kidney disease. Clin Kidney J 2017;10:i9-i15. [PMID: 29225818 DOI: 10.1093/ckj/sfx100] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
110 Cheng J, Kim J, Bieber SD, Lin E. Four years into MACRA: What has changed? Semin Dial 2020;33:26-34. [PMID: 31908062 DOI: 10.1111/sdi.12852] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
111 Hatamizadeh P, Ravel V, Lukowsky LR, Molnar MZ, Moradi H, Harley K, Pahl M, Kovesdy CP, Kalantar-Zadeh K. Iron indices and survival in maintenance hemodialysis patients with and without polycystic kidney disease. Nephrol Dial Transplant 2013;28:2889-98. [PMID: 24169614 DOI: 10.1093/ndt/gft411] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
112 Ramakrishnan SK, Shah YM. A central role for hypoxia-inducible factor (HIF)-2α in hepatic glucose homeostasis. Nutr Healthy Aging 2017;4:207-16. [PMID: 29276790 DOI: 10.3233/NHA-170022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
113 Katagiri D, Hinoshita F. Benefits and risks of erythrocyte-stimulating agents. World J Clin Urol 2014; 3(3): 258-263 [DOI: 10.5410/wjcu.v3.i3.258] [Reference Citation Analysis]
114 Morris M, Snedeker M, Reed G, Butcher B, Bradley J. Do iron guidelines translate into good clinical practice for patients on haemodialysis? J Ren Care 2014;40:49-54. [PMID: 24588980 DOI: 10.1111/j.1755-6686.2013.12036.x] [Reference Citation Analysis]
115 Coyne DW, Roger SD, Shin SK, Kim SG, Cadena AA, Moustafa MA, Chan TM, Besarab A, Chou W, Bradley C, Eyassu M, Leong R, Lee TT, Saikali KG, Szczech L, Yu KP. Roxadustat for CKD-related Anemia in Non-dialysis Patients. Kidney Int Rep 2021;6:624-35. [PMID: 33732977 DOI: 10.1016/j.ekir.2020.11.034] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
116 Stack AG, Alghali A, Li X, Ferguson JP, Casserly LF, Cronin CJ, Reddan DN, Hussein W, Elsayed ME. Quality of care and practice patterns in anaemia management at specialist kidney clinics in Ireland: a national study. Clin Kidney J 2018;11:99-107. [PMID: 29423209 DOI: 10.1093/ckj/sfx060] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
117 Shimamatsu K, Inamasu H. A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A "Half-and-Half" Combination Therapy. Curr Ther Res Clin Exp 2013;74:5-8. [PMID: 24384988 DOI: 10.1016/j.curtheres.2012.12.001] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
118 Narayanan V, Koshy C. Fatigue in cancer: a review of literature. Indian J Palliat Care. 2009;15:19-25. [PMID: 20606851 DOI: 10.4103/0973-1075.53507] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
119 Karaboyas A, Morgenstern H, Fleischer NL, Vanholder RC, Dhalwani NN, Schaeffner E, Schaubel DE, Akizawa T, James G, Sinsakul MV, Pisoni RL, Robinson BM. Inflammation and Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients: A Self-matched Longitudinal Study of Anemia Management in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Med 2020;2:286-96. [PMID: 32734248 DOI: 10.1016/j.xkme.2020.01.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
120 Hayashi T, Uemura Y, Kumagai M, Kimpara M, Kanno H, Ohashi Y; MIRACLE-CKD Study Group. Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study). Clin Exp Nephrol 2019;23:349-61. [PMID: 30291472 DOI: 10.1007/s10157-018-1649-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
121 Poinen K, Oliver MJ, Ravani P, Van der Veer SN, Jager KJ, Van Biesen W, Polkinghorne KR, Rosenfeld A, Lewin AM, Dulai M, Quinn RR. Willingness to participate in a randomized trial comparing catheters to fistulas for vascular access in incident hemodialysis patients: an international survey of nephrologists. Can J Kidney Health Dis 2016;3:33. [PMID: 27418966 DOI: 10.1186/s40697-016-0125-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
122 Lin E, MaCurdy T, Bhattacharya J. The Medicare Access and CHIP Reauthorization Act: Implications for Nephrology. J Am Soc Nephrol 2017;28:2590-6. [PMID: 28754790 DOI: 10.1681/ASN.2017040407] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
123 Nitta K. Pathogenesis and therapeutic implications of cardiorenal syndrome. Clin Exp Nephrol 2011;15:187-94. [PMID: 21104421 DOI: 10.1007/s10157-010-0374-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
124 Petzer V, Tymoszuk P, Asshoff M, Carvalho J, Papworth J, Deantonio C, Bayliss L, Wake MS, Seifert M, Brigo N, Valente de Souza L, Hilbe R, Grubwieser P, Demetz E, Dichtl S, Volani C, Berger S, Böhm F, Hoffmann A, Pfeifhofer-Obermair C, von Raffay L, Sopper S, Arndt S, Bosserhoff A, Kautz L, Perrier P, Nairz M, Wolf D, Weiss G, Germaschewski V, Theurl I. A fully human anti-BMP6 antibody reduces the need for erythropoietin in rodent models of the anemia of chronic disease. Blood 2020;136:1080-90. [PMID: 32438400 DOI: 10.1182/blood.2019004653] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
125 Palaka E, Grandy S, van Haalen H, McEwan P, Darlington O. The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes-A Systematic Literature Review. Int J Nephrol 2020;2020:7692376. [PMID: 32665863 DOI: 10.1155/2020/7692376] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
126 Slinin Y, Guo H, Gilbertson DT, Mau LW, Ensrud K, Rector T, Collins AJ, Ishani A. Meeting KDOQI guideline goals at hemodialysis initiation and survival during the first year. Clin J Am Soc Nephrol 2010;5:1574-81. [PMID: 20538835 DOI: 10.2215/CJN.01320210] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
127 Molnar MZ, Tabak AG, Alam A, Czira ME, Rudas A, Ujszaszi A, Beko G, Novak M, Kalantar-Zadeh K, Kovesdy CP, Mucsi I. Serum erythropoietin level and mortality in kidney transplant recipients. Clin J Am Soc Nephrol 2011;6:2879-86. [PMID: 21980181 DOI: 10.2215/CJN.05590611] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
128 Martin ER, Smith MT, Maroni BJ, Zuraw QC, deGoma EM. Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease. Am J Nephrol 2017;45:380-8. [PMID: 28343225 DOI: 10.1159/000464476] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 14.6] [Reference Citation Analysis]
129 Paige NM, Nagami GT. The top 10 things nephrologists wish every primary care physician knew. Mayo Clin Proc 2009;84:180-6. [PMID: 19181652 DOI: 10.1016/S0025-6196(11)60826-4] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
130 Xu L, Chen Y, Xie Z, He Q, Chen S, Wang W, Liu G, Liao Y, Lu C, Hao L, Sun J, Shi W, Liang X; China collaborative study on AKI (CCS-AKI). High hemoglobin is associated with increased in-hospital death in patients with chronic obstructive pulmonary disease and chronic kidney disease: a retrospective multicenter population-based study. BMC Pulm Med 2019;19:174. [PMID: 31533673 DOI: 10.1186/s12890-019-0933-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
131 Singh AK. Anaemia: Does the KDIGO guideline move the needle in CKD anaemia? Nat Rev Nephrol 2012;8:616-8. [PMID: 23007621 DOI: 10.1038/nrneph.2012.218] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
132 Mc Causland FR, Claggett B, Pfeffer MA, Burdmann EA, Eckardt KU, Levey AS, McMurray JJV, Remuzzi G, Singh AK, Solomon SD, Toto RD, Parfrey P. Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy Trial. Am J Nephrol 2017;46:488-97. [PMID: 29241199 DOI: 10.1159/000485326] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
133 Hatamizadeh P, Fonarow GC, Budoff MJ, Darabian S, Kovesdy CP, Kalantar-Zadeh K. Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol 2013;9:99-111. [PMID: 23247571 DOI: 10.1038/nrneph.2012.279] [Cited by in Crossref: 83] [Cited by in F6Publishing: 59] [Article Influence: 8.3] [Reference Citation Analysis]
134 Brier ME, Gaweda AE, Dailey A, Aronoff GR, Jacobs AA. Randomized trial of model predictive control for improved anemia management. Clin J Am Soc Nephrol 2010;5:814-20. [PMID: 20185598 DOI: 10.2215/CJN.07181009] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
135 Thamer M, Zhang Y, Kaufman J, Kshirsagar O, Cotter D, Hernán MA. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status. Am J Nephrol 2014;40:554-60. [PMID: 25592645 DOI: 10.1159/000370334] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
136 Zhang Y, Thamer M, Kaufman J, Cotter D, Hernán MA. Comparative effectiveness of two anemia management strategies for complex elderly dialysis patients. Med Care 2014;52 Suppl 3:S132-9. [PMID: 24561752 DOI: 10.1097/MLR.0b013e3182a53ca8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
137 Chengappa M, Herrmann S, Poonacha T. Self-reported Financial Conflict of Interest in Nephrology Clinical Practice Guidelines. Kidney Int Rep 2021;6:768-74. [PMID: 33732991 DOI: 10.1016/j.ekir.2020.12.014] [Reference Citation Analysis]
138 De Nicola L, Locatelli F, Conte G, Minutolo R. Responsiveness to erythropoiesis-stimulating agents in chronic kidney disease: does geography matter? Drugs 2014;74:159-68. [PMID: 24442793 DOI: 10.1007/s40265-013-0175-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
139 Birnie K, Caskey F, Ben-Shlomo Y, Sterne JA, Gilg J, Nitsch D, Tomson C. Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005-13. Nephrol Dial Transplant 2017;32:692-8. [PMID: 27190350 DOI: 10.1093/ndt/gfw043] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
140 Hartmann B, Czock D, Keller F. Drug therapy in patients with chronic renal failure. Dtsch Arztebl Int. 2010;107:647-655; quiz 655-656. [PMID: 20959896 DOI: 10.3238/arztebl.2010.0647] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
141 Shen Y, Wang J, Yuan J, Yang L, Yu F, Wang X, Zhao MH, Zhang L, Zha Y; Chinese Cohort Study of Chronic Kidney Disease (C-STRIDE). Anemia among Chinese patients with chronic kidney disease and its association with quality of life - results from the Chinese cohort study of chronic kidney disease (C-STRIDE). BMC Nephrol 2021;22:64. [PMID: 33618679 DOI: 10.1186/s12882-021-02247-8] [Reference Citation Analysis]
142 Rifkin DE, Coca SG, Kalantar-Zadeh K. Does AKI truly lead to CKD? J Am Soc Nephrol 2012;23:979-84. [PMID: 22460531 DOI: 10.1681/ASN.2011121185] [Cited by in Crossref: 120] [Cited by in F6Publishing: 62] [Article Influence: 12.0] [Reference Citation Analysis]
143 Koo HM, Kim CH, Doh FM, Lee MJ, Kim EJ, Han JH, Han JS, Oh HJ, Park JT, Han SH, Yoo TH, Kang SW. The relationship of initial transferrin saturation to cardiovascular parameters and outcomes in patients initiating dialysis. PLoS One 2014;9:e87231. [PMID: 24505281 DOI: 10.1371/journal.pone.0087231] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
144 Weiner DE, Sarnak MJ. Cardiovascular Disease in Patients with Chronic Kidney Disease. Chronic Kidney Disease, Dialysis, and Transplantation. Elsevier; 2010. pp. 128-44. [DOI: 10.1016/b978-1-4377-0987-2.00010-8] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
145 Park H, Liu X, Henry L, Harman J, Ross EA. Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015). BMC Nephrol 2018;19:318. [PMID: 30413150 DOI: 10.1186/s12882-018-1119-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
146 Ward F, Holian J, Murray PT. Drug therapies to delay the progression of chronic kidney disease. Clin Med (Lond) 2015;15:550-7. [PMID: 26621944 DOI: 10.7861/clinmedicine.15-6-550] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
147 Inrig JK, Barnhart HX, Reddan D, Patel UD, Sapp S, Califf RM, Singh AK, Szczech LA. Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial. Am J Kidney Dis 2012;60:390-401. [PMID: 22537421 DOI: 10.1053/j.ajkd.2012.03.009] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
148 Mathieu CM, Teta D, Lötscher N, Golshayan D, Gabutti L, Kiss D, Martin PY, Burnier M. Optimal and continuous anaemia control in a cohort of dialysis patients in Switzerland. BMC Nephrol 2008;9:16. [PMID: 19077225 DOI: 10.1186/1471-2369-9-16] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
149 Jie KE, van der Putten K, Wesseling S, Joles JA, Bergevoet MW, Pepers-de Kort F, Doevendans PA, Yasui Y, Liu Q, Verhaar MC, Gaillard CA, Braam B. Short-term erythropoietin treatment does not substantially modulate monocyte transcriptomes of patients with combined heart and renal failure. PLoS One 2012;7:e41339. [PMID: 22957013 DOI: 10.1371/journal.pone.0041339] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
150 Staples AO, Wong CS, Smith JM, Gipson DS, Filler G, Warady BA, Martz K, Greenbaum LA. Anemia and risk of hospitalization in pediatric chronic kidney disease. Clin J Am Soc Nephrol 2009;4:48-56. [PMID: 19056614 DOI: 10.2215/CJN.05301107] [Cited by in Crossref: 45] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
151 Parkash O, Iqbal R, Jafri F, Azam I, Jafri W. Frequency of poor quality of life and predictors of health related quality of life in cirrhosis at a tertiary care hospital Pakistan. BMC Res Notes. 2012;5:446. [PMID: 22905795 DOI: 10.1186/1556-0500.5.446] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
152 Atkinson MA, Furth SL. Anemia in children with chronic kidney disease. Nat Rev Nephrol 2011;7:635-41. [PMID: 21894183 DOI: 10.1038/nrneph.2011.115] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 4.2] [Reference Citation Analysis]
153 El-Kannishy GM, Megahed AF, Tawfik MM, El-Said G, Zakaria RT, Mohamed NA, Taha EM, Ammar AA, Abd Eltawab AM, Sayed-Ahmed NA. Obesity may be erythropoietin dose-saving in hemodialysis patients. Kidney Res Clin Pract 2018;37:148-56. [PMID: 29971210 DOI: 10.23876/j.krcp.2018.37.2.148] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
154 Curran MP, McCormack PL. Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs 2008;68:1139-56. [PMID: 18484803 DOI: 10.2165/00003495-200868080-00009] [Cited by in Crossref: 56] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
155 Haase VH. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl (2011) 2021;11:8-25. [PMID: 33777492 DOI: 10.1016/j.kisu.2020.12.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
156 Garlo K, Williams D, Lucas L, Wong R, Botler J, Abramson S, Parker MG. Severity of Anemia Predicts Hospital Length of Stay but Not Readmission in Patients with Chronic Kidney Disease: A Retrospective Cohort Study. Medicine (Baltimore) 2015;94:e964. [PMID: 26107682 DOI: 10.1097/MD.0000000000000964] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
157 Singh AK, Kelley K, Agarwal R. Interpreting results of clinical trials: a conceptual framework. Clin J Am Soc Nephrol 2008;3:1246-52. [PMID: 18728215 DOI: 10.2215/CJN.03580807] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
158 Zhang Y, Wang L, Dey S, Alnaeeli M, Suresh S, Rogers H, Teng R, Noguchi CT. Erythropoietin action in stress response, tissue maintenance and metabolism. Int J Mol Sci. 2014;15:10296-10333. [PMID: 24918289 DOI: 10.3390/ijms150610296] [Cited by in Crossref: 59] [Cited by in F6Publishing: 65] [Article Influence: 7.4] [Reference Citation Analysis]
159 Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Steenkamp R, Tomson CRV, Wheeler DC, Winearls CG, Ford I; on behalf of the PIVOTAL Trial investigators. Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. Am J Nephrol 2018;48:260-8. [PMID: 30304714 DOI: 10.1159/000493551] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
160 Streja E, Kovesdy CP, Greenland S, Kopple JD, McAllister CJ, Nissenson AR, Kalantar-Zadeh K. Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis. Am J Kidney Dis 2008;52:727-36. [PMID: 18760517 DOI: 10.1053/j.ajkd.2008.05.029] [Cited by in Crossref: 103] [Cited by in F6Publishing: 94] [Article Influence: 7.4] [Reference Citation Analysis]
161 Borawski B, Malyszko JS, Kwiatkowska M, Malyszko J. Current Status of Renal Anemia Pharmacotherapy-What Can We Offer Today. J Clin Med 2021;10:4149. [PMID: 34575261 DOI: 10.3390/jcm10184149] [Reference Citation Analysis]
162 Gilbertson DT, Hu Y, Peng Y, Maroni BJ, Wetmore JB. Variability in hemoglobin levels in hemodialysis patients in the current era: a retrospective cohort study. Clin Nephrol 2017;88:254-65. [PMID: 28899480 DOI: 10.5414/CN109031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
163 Eriksson D, Goldsmith D, Teitsson S, Jackson J, van Nooten F. Cross-sectional survey in CKD patients across Europe describing the association between quality of life and anaemia. BMC Nephrol 2016;17:97. [PMID: 27460779 DOI: 10.1186/s12882-016-0312-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
164 Ito H, Takeuchi Y, Ishida H, Otawa A, Shibayama A, Antoku S, Abe M, Mifune M, Togane M. Mild anemia is frequent and associated with micro- and macroangiopathies in patients with type 2 diabetes mellitus. J Diabetes Investig 2010;1:273-8. [PMID: 24843443 DOI: 10.1111/j.2040-1124.2010.00060.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
165 Yaseen M, Hassan W, Awad R, Ashqar B, Neyra J, Heister T, Malik O, El-Husseini A. Impact of Recent Clinical Trials on Nephrology Practice: Are We in a Stagnant Era? Kidney Dis (Basel). 2019;5:69-80. [PMID: 31019921 DOI: 10.1159/000495139] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
166 Nalado AM, Mahlangu JN, Waziri B, Duarte R, Paget G, Olorunfemi G, Naicker S. Ethnic prevalence of anemia and predictors of anemia among chronic kidney disease patients at a tertiary hospital in Johannesburg, South Africa. Int J Nephrol Renovasc Dis 2019;12:19-32. [PMID: 30858723 DOI: 10.2147/IJNRD.S179802] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
167 Šimetić L, Zibar L. Laboratory use of hepcidin in renal transplant recipients. Biochem Med (Zagreb) 2016;26:34-52. [PMID: 26981017 DOI: 10.11613/BM.2016.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
168 Padhi S, Panda SK. Acquired Pure Red Cell Aplasia and Recombinant Erythropoietin. Indian J Nephrol 2021;31:331-5. [PMID: 34584346 DOI: 10.4103/ijn.IJN_229_20] [Reference Citation Analysis]
169 Schneiderman LJ. Defining Medical Futility and Improving Medical Care. J Bioeth Inq 2011;8:123-31. [PMID: 21765643 DOI: 10.1007/s11673-011-9293-3] [Cited by in Crossref: 86] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
170 Lopes MB, Tu C, Zee J, Guedes M, Pisoni RL, Robinson BM, Foote B, Hedman K, James G, Lopes AA, Massy Z, Reichel H, Sloand J, Waechter S, Wong MMY, Pecoits-Filho R. A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps. Sci Rep 2021;11:1784. [PMID: 33469061 DOI: 10.1038/s41598-020-79254-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
171 Heinze G, Kainz A, Hörl WH, Oberbauer R. Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study. BMJ 2009;339:b4018. [PMID: 19854839 DOI: 10.1136/bmj.b4018] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 4.8] [Reference Citation Analysis]
172 Conway BN, Badders AN, Costacou T, Arthur JM, Innes KE. Perfluoroalkyl substances and kidney function in chronic kidney disease, anemia, and diabetes. Diabetes Metab Syndr Obes 2018;11:707-16. [PMID: 30532572 DOI: 10.2147/DMSO.S173809] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
173 Janmaat CJ, van Diepen M, van Hagen CC, Rotmans JI, Dekker FW, Dekkers OM. Decline of kidney function during the pre-dialysis period in chronic kidney disease patients: a systematic review and meta-analysis. Clin Epidemiol 2018;10:613-22. [PMID: 29872350 DOI: 10.2147/CLEP.S153367] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
174 Avram MM. Symposium proceedings. Perspective: irreversible progressive chronic kidney disease -- an overview. Kidney Int Suppl 2010;:S1-2. [PMID: 20671738 DOI: 10.1038/ki.2010.187] [Reference Citation Analysis]
175 Hamza E, Metzinger L, Metzinger-Le Meuth V. Uremic Toxins Affect Erythropoiesis during the Course of Chronic Kidney Disease: A Review. Cells 2020;9:E2039. [PMID: 32899941 DOI: 10.3390/cells9092039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
176 Kunadian V, Zorkun C, Gibson WJ, Nethala N, Harrigan C, Palmer AM, Ogando KJ, Biller LH, Lord EE, Williams SP, Lew ME, Ciaglo LN, Buros JL, Marble SJ, Gibson CM. Transfusion associated microchimerism: a heretofore little-recognized complication following transfusion. J Thromb Thrombolysis 2009;27:57-67. [PMID: 18766299 DOI: 10.1007/s11239-008-0268-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
177 Portolés J, Martín L, Broseta JJ, Cases A. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. Front Med (Lausanne) 2021;8:642296. [PMID: 33842503 DOI: 10.3389/fmed.2021.642296] [Reference Citation Analysis]
178 Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis 2013;61:44-56. [PMID: 22921639 DOI: 10.1053/j.ajkd.2012.07.014] [Cited by in Crossref: 103] [Cited by in F6Publishing: 79] [Article Influence: 10.3] [Reference Citation Analysis]
179 Swaminathan S, Mor V, Mehrotra R, Trivedi A. Medicare's payment strategy for end-stage renal disease now embraces bundled payment and pay-for-performance to cut costs. Health Aff (Millwood) 2012;31:2051-8. [PMID: 22949455 DOI: 10.1377/hlthaff.2012.0368] [Cited by in Crossref: 39] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
180 Bartnicki P, Kowalczyk M, Rysz J. The influence of the pleiotropic action of erythropoietin and its derivatives on nephroprotection. Med Sci Monit 2013;19:599-605. [PMID: 23872600 DOI: 10.12659/MSM.889023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
181 Budde K, Rath T, Kliem V. Anemia control in kidney transplant recipients using once-monthly continuous erythropoietin receptor activator: a prospective, observational study. J Transplant 2014;2014:179705. [PMID: 24883202 DOI: 10.1155/2014/179705] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
182 Na HY, Lee YK, Shin SK, Yang DH, Cheon W, Park JH, Lee JH, Song JO, Jo YI. A randomized crossover study of single biweekly administration of epoetin-α compared with darbepoetin-α in chronic kidney disease patients not receiving dialysis. Kidney Res Clin Pract 2014;33:210-6. [PMID: 26885479 DOI: 10.1016/j.krcp.2014.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
183 Zakai NA, French B, Arnold AM, Newman AB, Fried LF, Robbins J, Chaves P, Cushman M. Hemoglobin decline, function, and mortality in the elderly: the cardiovascular health study. Am J Hematol 2013;88:5-9. [PMID: 23044913 DOI: 10.1002/ajh.23336] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
184 Altincatal A, Macarthur RB, Teruya S, Helmke S, Maurer MS. A dosing algorithm for erythropoietin alpha in older adults with heart failure and a preserved ejection fraction. Cardiovasc Ther 2013;31:92-9. [PMID: 21884028 DOI: 10.1111/j.1755-5922.2011.00295.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
185 Anker SD, Toto R. Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients. NDT Plus 2009;2:i3-8. [PMID: 19461857 DOI: 10.1093/ndtplus/sfn174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
186 Li L, Chang A, Rostand SG, Hebert L, Appel LJ, Astor BC, Lipkowitz MS, Wright JT, Kendrick C, Wang X, Greene TH. A within-patient analysis for time-varying risk factors of CKD progression. J Am Soc Nephrol 2014;25:606-13. [PMID: 24231660 DOI: 10.1681/ASN.2013050464] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
187 Kowalczyk M, Banach M, Mikhailidis DP, Rysz J. Erythropoietin update 2011. Med Sci Monit 2011;17:RA240-247. [PMID: 22037755 DOI: 10.12659/msm.882037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
188 Eisenstein EL. DRIVE it home: making the case for prospective economic data collection in randomized clinical trials. Kidney International 2008;74:1507-9. [DOI: 10.1038/ki.2008.553] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
189 Pergola PE, Pecoits-Filho R, Winkelmayer WC, Spinowitz B, Rochette S, Thompson-Leduc P, Lefebvre P, Shafai G, Bozas A, Sanon M, Krasa HB. Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review. Pharmacoecon Open 2019;3:463-78. [PMID: 30968369 DOI: 10.1007/s41669-019-0132-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
190 Belonje AM, de Boer RA, Voors AA. Recombinant human Epo treatment: beneficial in chronic kidney disease, chronic heart failure, or both? Editorial to: "Correction of anemia with erythropoietin in chronic kidney disease (stage 3 or 4): effects on cardiac performance by Pappas et al.". Cardiovasc Drugs Ther 2008;22:1-2. [PMID: 18219567 DOI: 10.1007/s10557-008-6079-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
191 Levi A, Simard T, Glover C. Coronary Artery Disease in patients with End-Stage Kidney Disease; Current perspective and gaps of knowledge. Semin Dial 2020;33:187-97. [PMID: 32449824 DOI: 10.1111/sdi.12886] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
192 Mozos I. Mechanisms linking red blood cell disorders and cardiovascular diseases. Biomed Res Int 2015;2015:682054. [PMID: 25710019 DOI: 10.1155/2015/682054] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 5.6] [Reference Citation Analysis]
193 Pearl RG. Erythropoietin and organ protection: lessons from negative clinical trials. Crit Care 2014;18:526. [PMID: 25672222 DOI: 10.1186/s13054-014-0526-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
194 Kumar A, Auron M, Ereth M. Blood management. Anesthesiol Clin 2013;31:433-50. [PMID: 23711652 DOI: 10.1016/j.anclin.2013.02.001] [Reference Citation Analysis]
195 Böhlke M, Giesteira R, Castilho C, Pinheiro B, Irigoyen MC, Poli de Figueiredo CE. Acetylsalicylic acid mitigates erythropoietin-associated blood pressure increase in nonuremic rats. Clin Exp Hypertens 2015;37:235-40. [PMID: 25314608 DOI: 10.3109/10641963.2014.943403] [Reference Citation Analysis]
196 Finkelstein FO, Story K, Firanek C, Mendelssohn D, Barre P, Takano T, Soroka S, Mujais S. Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol 2009;4:33-8. [PMID: 18987300 DOI: 10.2215/CJN.00630208] [Cited by in Crossref: 89] [Cited by in F6Publishing: 37] [Article Influence: 6.4] [Reference Citation Analysis]
197 Johnson AC, Becker K, Zager RA. Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury. Am J Physiol Renal Physiol 2010;299:F426-35. [PMID: 20504881 DOI: 10.1152/ajprenal.00248.2010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
198 Staples A, Wong C. Risk factors for progression of chronic kidney disease. Curr Opin Pediatr 2010;22:161-9. [PMID: 20090523 DOI: 10.1097/MOP.0b013e328336ebb0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
199 Winkelmayer WC, Chandraker A. Pottransplantation anemia: management and rationale. Clin J Am Soc Nephrol 2008;3 Suppl 2:S49-55. [PMID: 18309003 DOI: 10.2215/CJN.03290807] [Cited by in Crossref: 53] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
200 Tanaka T, Nangaku M, Imai E, Tsubakihara Y, Kamai M, Wada M, Asada S, Akizawa T. Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan. Clin Exp Nephrol 2019;23:231-43. [PMID: 30182223 DOI: 10.1007/s10157-018-1632-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
201 Gardiner R, Roshan D, Brennan A, Connolly D, Murray S, Reddan D. Trends in the treatment of chronic kidney disease-associated anaemia in a cohort of haemodialysis patients: the Irish experience. Ir J Med Sci 2019;188:223-30. [PMID: 29704093 DOI: 10.1007/s11845-018-1823-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
202 Barbieri C, Bolzoni E, Mari F, Cattinelli I, Bellocchio F, Martin JD, Amato C, Stopper A, Gatti E, Macdougall IC, Stuard S, Canaud B. Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients. PLoS One 2016;11:e0148938. [PMID: 26939055 DOI: 10.1371/journal.pone.0148938] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
203 Palazzuoli A, Quatrini I, Calabrò A, Antonelli G, Caputo M, Campagna MS, Franci B, Nuti R. Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome. Clin Exp Med. 2011;11:43-48. [PMID: 20512394 DOI: 10.1007/s10238-010-0100-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
204 Wish JB, Anker SD, Butler J, Cases A, Stack AG, Macdougall IC. Iron Deficiency in CKD Without Concomitant Anemia. Kidney Int Rep 2021;6:2752-62. [PMID: 34805628 DOI: 10.1016/j.ekir.2021.07.032] [Reference Citation Analysis]
205 Derebail VK, Lacson EK Jr, Kshirsagar AV, Key NS, Hogan SL, Hakim RM, Mooney A, Jani CM, Johnson C, Hu Y, Falk RJ, Lazarus JM. Sickle trait in African-American hemodialysis patients and higher erythropoiesis-stimulating agent dose. J Am Soc Nephrol 2014;25:819-26. [PMID: 24459231 DOI: 10.1681/ASN.2013060575] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
206 Unruh ML, Larive B, Chertow GM, Eggers PW, Garg AX, Gassman J, Tarallo M, Finkelstein FO, Kimmel PL; FHN Trials Group. Effects of 6-times-weekly versus 3-times-weekly hemodialysis on depressive symptoms and self-reported mental health: Frequent Hemodialysis Network (FHN) Trials. Am J Kidney Dis 2013;61:748-58. [PMID: 23332990 DOI: 10.1053/j.ajkd.2012.11.047] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
207 Piety NZ, Reinhart WH, Stutz J, Shevkoplyas SS. Optimal hematocrit in an artificial microvascular network. Transfusion 2017;57:2257-66. [PMID: 28681482 DOI: 10.1111/trf.14213] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
208 Thamer M, Zhang Y, Lai D, Kshirsagar O, Cotter D. Influence of safety warnings on ESA prescribing among dialysis patients using an interrupted time series. BMC Nephrol 2013;14:172. [PMID: 23927675 DOI: 10.1186/1471-2369-14-172] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
209 Qunibi WY. Is It Too Much of a Good Thing? A New Era in Phosphate Binder Therapy in ESRD. J Am Soc Nephrol 2015;26:2311-3. [PMID: 25736046 DOI: 10.1681/ASN.2015020135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
210 Lewis EF, Pfeffer MA, Feng A, Uno H, McMurray JJ, Toto R, Gandra SR, Solomon SD, Moustafa M, Macdougall IC. Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. Clin J Am Soc Nephrol. 2011;6:845-855. [PMID: 21212421 DOI: 10.2215/cjn.06450710] [Cited by in Crossref: 39] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
211 Eisenga MF, De Jong MA, Van der Meer P, Leaf DE, Huls G, Nolte IM, Gaillard CAJM, Bakker SJL, De Borst MH. Iron deficiency, elevated erythropoietin, fibroblast growth factor 23, and mortality in the general population of the Netherlands: A cohort study. PLoS Med 2019;16:e1002818. [PMID: 31170159 DOI: 10.1371/journal.pmed.1002818] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
212 Yilmaz M, Kircelli F, Artan AS, Oto O, Asci G, Gunestepe K, Basci A, Ok E, Sever MS. Naturally nonanemic dialysis patients: Who are they? Hemodial Int 2016;20:522-9. [PMID: 27147461 DOI: 10.1111/hdi.12425] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
213 Lapchak PA. Erythropoietin molecules to treat acute ischemic stroke: a translational dilemma! Expert Opin Investig Drugs 2010;19:1179-86. [PMID: 20828227 DOI: 10.1517/13543784.2010.517954] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
214 Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF. Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease. Cochrane Database Syst Rev 2017;8:CD009904. [PMID: 28782299 DOI: 10.1002/14651858.CD009904.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
215 Becker KA, Jones JJ. An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat. Adv Ther 2018;35:5-11. [PMID: 29285707 DOI: 10.1007/s12325-017-0655-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
216 Ookawara S, Ito K, Sasabuchi Y, Hayasaka H, Kofuji M, Uchida T, Horigome K, Imai S, Akikawa T, Wada N, Kiryu S, Imada S, Shindo M, Miyazawa H, Hirai K, Onishi Y, Shimoyama H, Watanabe A, Tabei K, Morishita Y. Associations of cerebral oxygenation with hemoglobin levels evaluated by near-infrared spectroscopy in hemodialysis patients. PLoS One 2020;15:e0236720. [PMID: 32776946 DOI: 10.1371/journal.pone.0236720] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
217 Akizawa T, Makino H, Matsuo S, Watanabe T, Imai E, Nitta K, Ohashi Y, Hishida A; Chronic Kidney Disease Japan Cohort Study Group. Management of anemia in chronic kidney disease patients: baseline findings from Chronic Kidney Disease Japan Cohort Study. Clin Exp Nephrol 2011;15:248-57. [PMID: 21234785 DOI: 10.1007/s10157-010-0396-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
218 Arnold J, Sims D, Ferro CJ. Modulation of stroke risk in chronic kidney disease. Clin Kidney J 2016;9:29-38. [PMID: 26798458 DOI: 10.1093/ckj/sfv136] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
219 Coronado Daza J, Martí-Carvajal AJ, Ariza García A, Rodelo Ceballos J, Yomayusa González N, Páez-Canro C, Loza Munárriz C, Urrútia G. Early versus delayed erythropoietin for the anaemia of end-stage kidney disease. Cochrane Database Syst Rev 2015;:CD011122. [PMID: 26671531 DOI: 10.1002/14651858.CD011122.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
220 . Chapter 3: Use of ESAs and other agents to treat anemia in CKD. Kidney Int Suppl (2011) 2012;2:299-310. [PMID: 25018950 DOI: 10.1038/kisup.2012.35] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
221 Bradbury BD, Danese MD, Gleeson M, Critchlow CW. Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL. Clin J Am Soc Nephrol 2009;4:630-7. [PMID: 19261826 DOI: 10.2215/CJN.03580708] [Cited by in Crossref: 37] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
222 Bren A, Arnol M, Kandus A, Varl J, Oblak M, Lindič J, Pajek J, Knap B, Kovač D, Mlinšek G, Buturović-Ponikvar J. Treatment of anemia with epoetin in kidney transplant recipients. Ther Apher Dial 2011;15:257-60. [PMID: 21624072 DOI: 10.1111/j.1744-9987.2011.00947.x] [Reference Citation Analysis]
223 Chan E, Hemmelgarn B, Klarenbach S, Manns B, Mustafa R, Nesrallah G, McQuillan R. Choosing Wisely: The Canadian Society of Nephrology's List of 5 Items Physicians and Patients Should Question. Can J Kidney Health Dis 2017;4:2054358117695570. [PMID: 28321324 DOI: 10.1177/2054358117695570] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
224 Lee J, Vernet A, Gruber NG, Kready KM, Burrill DR, Way JC, Silver PA. Rational engineering of an erythropoietin fusion protein to treat hypoxia. Protein Eng Des Sel 2021;34:gzab025. [PMID: 34725710 DOI: 10.1093/protein/gzab025] [Reference Citation Analysis]
225 Watschinger B, Salmhofer H, Horn S, Neyer U, Wiesinger T, Wiesholzer M, Erb H, Jaeger C, Hemetsberger M, Rosenkranz AR. The MAINTAIN study--managing hemoglobin variability with darbepoetin alfa in dialysis patients experiencing a severe drop in hemoglobin. Wien Klin Wochenschr 2013;125:71-82. [PMID: 23299452 DOI: 10.1007/s00508-012-0311-1] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
226 Locatelli F, Del Vecchio L. A new paradigm in treating patients with chronic kidney disease and anaemia after a journey lasting more than 35 years. Nephrol Dial Transplant 2021;36:1559-63. [PMID: 34014305 DOI: 10.1093/ndt/gfab177] [Reference Citation Analysis]
227 Kupper N, Pelle AJ, Szabó BM, Denollet J. The relationship between Type D personality, affective symptoms and hemoglobin levels in chronic heart failure. PLoS One 2013;8:e58370. [PMID: 23472188 DOI: 10.1371/journal.pone.0058370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
228 Choi D, Schroer SA, Lu SY, Wang L, Wu X, Liu Y, Zhang Y, Gaisano HY, Wagner KU, Wu H. Erythropoietin protects against diabetes through direct effects on pancreatic beta cells. J Exp Med. 2010;207:2831-2842. [PMID: 21149549 DOI: 10.1084/jem.20100665] [Cited by in Crossref: 100] [Cited by in F6Publishing: 97] [Article Influence: 8.3] [Reference Citation Analysis]
229 Mercadal L, Metzger M, Casadevall N, Haymann JP, Karras A, Boffa JJ, Flamant M, Vrtovsnik F, Stengel B, Froissart M; NephroTest Study Group. Timing and determinants of erythropoietin deficiency in chronic kidney disease. Clin J Am Soc Nephrol 2012;7:35-42. [PMID: 22096037 DOI: 10.2215/CJN.04690511] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
230 Arcidiacono MV, Martinez-Alonso M, Belart M, Vilar A, Martín M, Craver L, Betriu À, Mauricio D, Valdivielso JM, Fernández E, Borràs M. High Levels of Hemoglobin Promote Carotid Adventitial Vasa Vasorum Neoangiogenesis in Chronic Kidney Disease. Mediators Inflamm 2017;2017:3795142. [PMID: 28133420 DOI: 10.1155/2017/3795142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
231 Khan UA, Garg AX, Parikh CR, Coca SG. Prevention of chronic kidney disease and subsequent effect on mortality: a systematic review and meta-analysis. PLoS One 2013;8:e71784. [PMID: 24009665 DOI: 10.1371/journal.pone.0071784] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
232 Gul A, Miskulin D, Gassman J, Harford A, Horowitz B, Chen J, Paine S, Bedrick E, Kusek JW, Unruh M, Zager P; BID Pilot Study Investigators. Design of the Blood Pressure Goals in Dialysis pilot study. Am J Med Sci 2014;347:125-30. [PMID: 23377167 DOI: 10.1097/MAJ.0b013e31827daee5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
233 Kuo KL, Hung SC, Tseng WC, Tsai MT, Liu JS, Lin MH, Hsu CC, Tarng DC; Taiwan Society of Nephrology Renal Registry Data System. Association of Anemia and Iron Parameters With Mortality Among Patients Undergoing Prevalent Hemodialysis in Taiwan: The AIM - HD Study. J Am Heart Assoc 2018;7:e009206. [PMID: 30371224 DOI: 10.1161/JAHA.118.009206] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
234 Erickson KF, Winkelmayer WC. Evaluating the Evidence behind Policy Mandates in US Dialysis Care. J Am Soc Nephrol 2018;29:2777-9. [PMID: 30389727 DOI: 10.1681/ASN.2018090905] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
235 Parfrey PS. In the Literature: On Clinical Performance Measures and Outcomes Among Hemodialysis Patients. American Journal of Kidney Diseases 2007;49:352-5. [DOI: 10.1053/j.ajkd.2007.01.019] [Cited by in Crossref: 6] [Article Influence: 0.4] [Reference Citation Analysis]
236 Alabdan N, AlRuthia Y, Yates MED, Sales I, Finch CK, Hudson JQ. Predictors of adherence to a new erythropoiesis-stimulating agent inpatient ordering policy: A cross-sectional study. PLoS One 2017;12:e0188390. [PMID: 29182650 DOI: 10.1371/journal.pone.0188390] [Reference Citation Analysis]
237 van der Weerd NC, Den Hoedt CH, Blankestijn PJ, Bots ML, van den Dorpel MA, Lévesque R, Mazairac AH, Nubé MJ, Penne EL, ter Wee PM, Grooteman MP; CONTRAST Investigators. Resistance to erythropoiesis stimulating agents in patients treated with online hemodiafiltration and ultrapure low-flux hemodialysis: results from a randomized controlled trial (CONTRAST). PLoS One 2014;9:e94434. [PMID: 24743493 DOI: 10.1371/journal.pone.0094434] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
238 Gordon J, Kopp JB. Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy. Adv Chronic Kidney Dis 2011;18:300-11. [PMID: 21782136 DOI: 10.1053/j.ackd.2011.06.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
239 Jager KJ, Lindholm B, Goldsmith D, Fliser D, Wiecek A, Suleymanlar G, Ortiz A, Massy Z, Martinez-Castelao A, Agarwal R, Blankestijn PJ, Covic A, London G, Zoccali C, Dekker FW; for EUropean REnal and CArdiovascular Medicine working group of the European Renal Association–European Dialysis and Transplant Association (ERA–EDTA). Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link? Kidney Int Suppl (2011) 2011;1:21-3. [PMID: 25028623 DOI: 10.1038/kisup.2011.7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
240 Evstatiev R. [Iron deficiency, thrombocytosis and thromboembolism]. Wien Med Wochenschr 2016;166:437-46. [PMID: 27682430 DOI: 10.1007/s10354-016-0514-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
241 Joshi AD, Holdford DA, Brophy DF, Harpe SE, Mays D, Gehr TW. Utilization Patterns of IV Iron and Erythropoiesis Stimulating Agents in Anemic Chronic Kidney Disease Patients: A Multihospital Study. Anemia 2012;2012:248430. [PMID: 22577528 DOI: 10.1155/2012/248430] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
242 Thamer M, Zhang Y, Kshirsagar O, Cotter DJ, Kaufman JS. Erythropoiesis-stimulating agent use among non-dialysis-dependent CKD patients before and after the trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) using a large US health plan database. Am J Kidney Dis 2014;64:706-13. [PMID: 25011692 DOI: 10.1053/j.ajkd.2014.05.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
243 Heidenreich S, Leistikow F, Zinn S, Baumann J, Atzeni A, Bajeski V, Dietzmann J, Dragoun GP; SUPRA Study Group. Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: results from the non-interventional, single-cohort, multicentre, SUPRA study. Clin Drug Investig 2012;32:99-110. [PMID: 22117178 DOI: 10.2165/11594040-000000000-00000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
244 Castillo N, García-García P, Rivero A, Jiménez-Sosa A, Macía M, Getino MA, Méndez ML, García-Pérez J, Navarro-González JF. Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study. BMC Nephrol 2012;13:60. [PMID: 22799577 DOI: 10.1186/1471-2369-13-60] [Cited by in Crossref: 7] [Article Influence: 0.7] [Reference Citation Analysis]
245 Alani H, Tamimi A, Tamimi N. Cardiovascular co-morbidity in chronic kidney disease: Current knowledge and future research needs. World J Nephrol 2014; 3(4): 156-168 [PMID: 25374809 DOI: 10.5527/wjn.v3.i4.156] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
246 Diebold M, Kistler AD. Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing. BMC Nephrol 2019;20:76. [PMID: 30823916 DOI: 10.1186/s12882-019-1263-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
247 Ronco C, Kellum JA, Bellomo R, House AA. Potential interventions in sepsis-related acute kidney injury. Clin J Am Soc Nephrol 2008;3:531-44. [PMID: 18235149 DOI: 10.2215/CJN.03830907] [Cited by in Crossref: 54] [Cited by in F6Publishing: 16] [Article Influence: 3.9] [Reference Citation Analysis]
248 Japanese Society of Nephrology. Evidence-based practice guideline for the treatment of CKD. Clin Exp Nephrol. 2009;13:537-566. [PMID: 19960305 DOI: 10.1007/s10157-009-0237-8] [Cited by in Crossref: 84] [Cited by in F6Publishing: 77] [Article Influence: 7.0] [Reference Citation Analysis]
249 Kim SM, Kim KM, Kwon SK, Kim HY. Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease. J Korean Med Sci 2016;31:55-60. [PMID: 26770038 DOI: 10.3346/jkms.2016.31.1.55] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
250 Macdougall IC, Bock A, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Cushway T, Roger SD; FIND-CKD Study Investigators. The FIND-CKD study--a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. Nephrol Dial Transplant 2014;29:843-50. [PMID: 24170814 DOI: 10.1093/ndt/gft424] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.9] [Reference Citation Analysis]
251 Khan AI, Coldewey SM, Patel NS, Rogazzo M, Collino M, Yaqoob MM, Radermacher P, Kapoor A, Thiemermann C. Erythropoietin attenuates cardiac dysfunction in experimental sepsis in mice via activation of the β-common receptor. Dis Model Mech. 2013;6:1021-1030. [PMID: 23519033 DOI: 10.1242/dmm.011908] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
252 Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S; Dialysis Advisory Group of the American Society of Nephrology. Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am Soc Nephrol 2015;26:1238-47. [PMID: 25542967 DOI: 10.1681/ASN.2014090922] [Cited by in Crossref: 56] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
253 Sakaguchi Y, Hamano T, Wada A, Masakane I. Types of Erythropoietin-Stimulating Agents and Mortality among Patients Undergoing Hemodialysis. J Am Soc Nephrol 2019;30:1037-48. [PMID: 31015255 DOI: 10.1681/ASN.2018101007] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 12.7] [Reference Citation Analysis]
254 Charytan C, Manllo-Karim R, Martin ER, Steer D, Bernardo M, Dua SL, Moustafa MA, Saha G, Bradley C, Eyassu M, Leong R, Saikali KG, Liu C, Szczech L, Yu KP. A Randomized Trial of Roxadustat in Anemia of Kidney Failure: SIERRAS Study. Kidney Int Rep 2021;6:1829-39. [PMID: 34307977 DOI: 10.1016/j.ekir.2021.04.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
255 Zelnick LR, Batacchi ZO, Ahmad I, Dighe A, Little RR, Trence DL, Hirsch IB, de Boer IH. Continuous Glucose Monitoring and Use of Alternative Markers To Assess Glycemia in Chronic Kidney Disease. Diabetes Care 2020;43:2379-87. [PMID: 32788282 DOI: 10.2337/dc20-0915] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
256 Zhang Y, Ren S, Xue H, Wang AY, Zou Y, Cai Y, He J, Yuan X, Jiang F, Wei J, Yang D, He D, Hu S, Lei M, Deng F, Chen J, Wang X, He Q, Li G, Hong D. Roxadustat in treating anemia in dialysis patients (ROAD): protocol and rationale of a multicenter prospective observational cohort study. BMC Nephrol 2021;22:28. [PMID: 33441103 DOI: 10.1186/s12882-021-02229-w] [Reference Citation Analysis]
257 Hamad A, Ezzat H, Latif Ghonimi TA, Ibrahim R, Ramadan F, Noor N, Yasin F, Ismail S, Al-Ali F. Effects of novel anemia nurse manager program on hemodialysis: a retrospective study from Qatar. Qatar Med J 2021;2021:46. [PMID: 34733708 DOI: 10.5339/qmj.2021.46] [Reference Citation Analysis]
258 Rattanasompattikul M, Molnar MZ, Zaritsky JJ, Hatamizadeh P, Jing J, Norris KC, Kovesdy CP, Kalantar-Zadeh K. Association of malnutrition-inflammation complex and responsiveness to erythropoiesis-stimulating agents in long-term hemodialysis patients. Nephrol Dial Transplant 2013;28:1936-45. [PMID: 23045431 DOI: 10.1093/ndt/gfs368] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
259 Pollak VE, Lorch JA, Shukla R, Satwah S. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. BMC Nephrol 2009;10:6. [PMID: 19245700 DOI: 10.1186/1471-2369-10-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
260 Kohagura K, Tomiyama N, Kinjo K, Takishita S, Iseki K. Prevalence of anemia according to stage of chronic kidney disease in a large screening cohort of Japanese. Clin Exp Nephrol 2009;13:614-20. [PMID: 19526304 DOI: 10.1007/s10157-009-0197-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
261 Segall L, Nistor I, Covic A. Heart failure in patients with chronic kidney disease: a systematic integrative review. Biomed Res Int 2014;2014:937398. [PMID: 24959595 DOI: 10.1155/2014/937398] [Cited by in Crossref: 67] [Cited by in F6Publishing: 59] [Article Influence: 8.4] [Reference Citation Analysis]
262 Aapro M, Gascón P, Patel K, Rodgers GM, Fung S, Arantes LH Jr, Wish J. Erythropoiesis-Stimulating Agents in the Management of Anemia in Chronic Kidney Disease or Cancer: A Historical Perspective. Front Pharmacol 2018;9:1498. [PMID: 30687083 DOI: 10.3389/fphar.2018.01498] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
263 Whittaker CF, Miklich MA, Patel RS, Fink JC. Medication Safety Principles and Practice in CKD. Clin J Am Soc Nephrol 2018;13:1738-46. [PMID: 29915131 DOI: 10.2215/CJN.00580118] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
264 Goodnough LT, Maniatis A, Earnshaw P, Benoni G, Beris P, Bisbe E, Fergusson DA, Gombotz H, Habler O, Monk TG. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth. 2011;106:13-22. [PMID: 21148637 DOI: 10.1093/bja/aeq361] [Cited by in Crossref: 320] [Cited by in F6Publishing: 275] [Article Influence: 29.1] [Reference Citation Analysis]
265 Xu H, Lindholm B, Lundström UH, Heimbürger O, Stendahl M, Rydell H, Segelmark M, Carrero JJ, Evans M. Treatment practices and outcomes in incident peritoneal dialysis patients: the Swedish Renal Registry 2006-2015. Clin Kidney J 2021;14:2539-47. [PMID: 34950465 DOI: 10.1093/ckj/sfab130] [Reference Citation Analysis]
266 Butt AA, Umbleja T, Andersen JW, Chung RT, Sherman KE; ACTG A5178 Study Team. The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin. Aliment Pharmacol Ther 2011;33:1234-44. [PMID: 21535051 DOI: 10.1111/j.1365-2036.2011.04648.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
267 Lea JP, Norris K, Agodoa L. The role of anemia management in improving outcomes for African-Americans with chronic kidney disease. Am J Nephrol 2008;28:732-43. [PMID: 18434712 DOI: 10.1159/000127981] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
268 de Francisco AL, Stenvinkel P, Vaulont S. Inflammation and its impact on anaemia in chronic kidney disease: from haemoglobin variability to hyporesponsiveness. NDT Plus 2009;2:i18-26. [PMID: 19461856 DOI: 10.1093/ndtplus/sfn176] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
269 de Francisco AL. Key insights into present and future treatments of anaemia in CKD patients. NDT Plus 2009;2:i1-2. [PMID: 19461858 DOI: 10.1093/ndtplus/sfn173] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
270 Swaminathan S, Mor V, Mehrotra R, Trivedi AN. Effect of Medicare dialysis payment reform on use of erythropoiesis stimulating agents. Health Serv Res 2015;50:790-808. [PMID: 25355431 DOI: 10.1111/1475-6773.12252] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
271 Hayashi T, Maruyama S, Nangaku M, Narita I, Hirakata H, Tanabe K, Morita S, Tsubakihara Y, Imai E, Akizawa T; PREDICT Investigators. Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial. Clin J Am Soc Nephrol 2020;15:608-15. [PMID: 32245781 DOI: 10.2215/CJN.08900719] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
272 Cohen RS, Karlin P, Yushak M, Mancini D, Maurer MS. The effect of erythropoietin on exercise capacity, left ventricular remodeling, pressure-volume relationships, and quality of life in older patients with anemia and heart failure with preserved ejection fraction. Congest Heart Fail 2010;16:96-103. [PMID: 20557328 DOI: 10.1111/j.1751-7133.2009.00135.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
273 Tsuruya K, Torisu K, Yoshida H, Yamada S, Tanaka S, Tsuchimoto A, Eriguchi M, Fujisaki K, Masutani K, Kitazono T. Positive association of residual kidney function with hemoglobin level in patients on peritoneal dialysis independent of endogenous erythropoietin concentration. Ren Replace Ther 2017;3. [DOI: 10.1186/s41100-017-0126-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
274 Kalra PA. Introducing iron isomaltoside 1000 (Monofer®)-development rationale and clinical experience. NDT Plus 2011;4:i10-3. [PMID: 27045417 DOI: 10.1093/ndtplus/sfr042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
275 Patel UD, Grab J, Kosiborod M, Lytle B, Peterson ED, Alexander KP. Impact of anemia on physical function and survival among patients with coronary artery disease. Clin Cardiol 2008;31:546-50. [PMID: 19006118 DOI: 10.1002/clc.20283] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
276 Wetmore JB, Li S, Yan H, Xu H, Peng Y, Sinsakul MV, Liu J, Gilbertson DT. Predialysis anemia management and outcomes following dialysis initiation: A retrospective cohort analysis. PLoS One 2018;13:e0203767. [PMID: 30256836 DOI: 10.1371/journal.pone.0203767] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
277 Hung SC, Kuo KL, Peng CH, Wu CH, Wang YC, Tarng DC. Association of fluid retention with anemia and clinical outcomes among patients with chronic kidney disease. J Am Heart Assoc 2015;4:e001480. [PMID: 25559015 DOI: 10.1161/JAHA.114.001480] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
278 Kato H, Nangaku M, Hirakata H, Wada T, Hayashi T, Sato H, Yamazaki Y, Masaki T, Kagimura T, Yamamoto H, Hase H, Kamouchi M, Imai E, Mizuno K, Iwasaki M, Akizawa T, Tsubakihara Y, Maruyama S, Narita I. Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial). Clin Exp Nephrol 2018;22:78-84. [PMID: 28660446 DOI: 10.1007/s10157-017-1427-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
279 Pai AB, Garba AO. Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease or another dark cloud? J Blood Med. 2012;3:77-85. [PMID: 22973119 DOI: 10.2147/jbm.s29204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 20] [Article Influence: 0.5] [Reference Citation Analysis]
280 Warren JS, Zhao Y, Yung R, Desai A. Recombinant human erythropoietin suppresses endothelial cell apoptosis and reduces the ratio of Bax to Bcl-2 proteins in the aortas of apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011;57:424-33. [PMID: 21242808 DOI: 10.1097/FJC.0b013e31820d92fd] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
281 Van Buren P, Velez RL, Vaziri ND, Zhou XJ. Iron overdose: a contributor to adverse outcomes in randomized trials of anemia correction in CKD. Int Urol Nephrol 2012;44:499-507. [PMID: 21744260 DOI: 10.1007/s11255-011-0028-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
282 Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Nolen JG, Roger SD; FIND-CKD Study Investigators. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014;29:2075-84. [PMID: 24891437 DOI: 10.1093/ndt/gfu201] [Cited by in Crossref: 149] [Cited by in F6Publishing: 127] [Article Influence: 18.6] [Reference Citation Analysis]
283 Hanna RM, Streja E, Kalantar-Zadeh K. Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin. Adv Ther 2021;38:52-75. [PMID: 33123967 DOI: 10.1007/s12325-020-01524-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
284 de Francisco AL. Individualizing anaemia therapy. NDT Plus 2010;3:519-26. [PMID: 25949459 DOI: 10.1093/ndtplus/sfq164] [Reference Citation Analysis]
285 Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol 2009;4:755-62. [PMID: 19339417 DOI: 10.2215/CJN.02730608] [Cited by in Crossref: 73] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
286 Chhabra D, Grafals M, Skaro AI, Parker M, Gallon L. Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection. Clin J Am Soc Nephrol 2008;3:1168-74. [PMID: 18463170 DOI: 10.2215/CJN.04641007] [Cited by in Crossref: 67] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
287 Jordan J, Breckles J, Leung V, Hopkins M, Battistella M. Conversion from epoetin alfa to darbepoetin alfa: effects on patients' hemoglobin and costs to canadian dialysis centres. Can J Hosp Pharm 2012;65:443-9. [PMID: 23288954 DOI: 10.4212/cjhp.v65i6.1192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
288 George S, McCann M. A nurse prescriber-led protocol for anaemia management in established haemodialysis patients: A retrospective study. J Clin Nurs 2020;29:2535-43. [PMID: 32267027 DOI: 10.1111/jocn.15275] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
289 Jing Z, Wei-jie Y, Nan Z, Yi Z, Ling W. Hemoglobin targets for chronic kidney disease patients with anemia: a systematic review and meta-analysis. PLoS One 2012;7:e43655. [PMID: 22952731 DOI: 10.1371/journal.pone.0043655] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
290 Biggar P, Kim GH. Treatment of renal anemia: Erythropoiesis stimulating agents and beyond. Kidney Res Clin Pract 2017;36:209-23. [PMID: 28904872 DOI: 10.23876/j.krcp.2017.36.3.209] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
291 Schonder KS, Corman SL, Hung WY. Early risk factors for persistent anemia after kidney transplantation. Pharmacotherapy 2010;30:1214-20. [PMID: 21114388 DOI: 10.1592/phco.30.12.1214] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
292 Finkelstein FO, van Nooten F, Wiklund I, Trundell D, Cella D. Measurement properties of the Short Form-36 (SF-36) and the Functional Assessment of Cancer Therapy - Anemia (FACT-An) in patients with anemia associated with chronic kidney disease. Health Qual Life Outcomes 2018;16:111. [PMID: 29855366 DOI: 10.1186/s12955-018-0933-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
293 Dopsaj V, Topić A, Savković M, Milinković N, Novaković I, Ćujić D, Simić-Ogrizović S. Associations of Common Variants in HFE and TMPRSS6 Genes with Hepcidin-25 and Iron Status Parameters in Patients with End-Stage Renal Disease. Dis Markers 2019;2019:4864370. [PMID: 30984307 DOI: 10.1155/2019/4864370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
294 Mima A. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages. Eur J Pharmacol 2021;912:174583. [PMID: 34678238 DOI: 10.1016/j.ejphar.2021.174583] [Reference Citation Analysis]
295 Garattini S, Perico N. Drug development: how academia, industry and authorities interact. Nat Rev Nephrol 2014;10:602-10. [PMID: 25092151 DOI: 10.1038/nrneph.2014.133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
296 Cano F, Alarcon C, Azocar M, Lizama C, Maria Lillo A, Delucchi A, Gonzalez M, Arellano P, Delgado I, Droguett MT. Continuous EPO receptor activator therapy of anemia in children under peritoneal dialysis. Pediatr Nephrol 2011;26:1303-10. [PMID: 21416403 DOI: 10.1007/s00467-011-1846-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
297 Tang M, Zhu C, Yan T, Zhou Y, Lv Q, Chuan J. Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat. Front Pharmacol 2021;12:658079. [PMID: 34276361 DOI: 10.3389/fphar.2021.658079] [Reference Citation Analysis]
298 Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int. 2008;74:791-798. [PMID: 18596733 DOI: 10.1038/ki.2008.295] [Cited by in Crossref: 347] [Cited by in F6Publishing: 291] [Article Influence: 24.8] [Reference Citation Analysis]
299 Keithi-Reddy SR, Addabbo F, Patel TV, Mittal BV, Goligorsky MS, Singh AK. Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int 2008;74:782-90. [PMID: 18547996 DOI: 10.1038/ki.2008.245] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
300 Anand I, Gupta P. How I treat anemia in heart failure. Blood 2020;136:790-800. [PMID: 31895946 DOI: 10.1182/blood.2019004004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
301 Derebail VK, Nachman PH, Key NS, Ansede H, Falk RJ, Rosamond WD, Kshirsagar AV. Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients. Kidney Int 2011;80:992-9. [PMID: 21849972 DOI: 10.1038/ki.2011.247] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
302 Pollock C, Neuen BL. Sodium-Glucose Cotransporter 2 Inhibition: Rationale and Mechanisms for Kidney and Cardiovascular Protection in People With and Without Diabetes. Adv Chronic Kidney Dis 2021;28:298-308. [PMID: 34922686 DOI: 10.1053/j.ackd.2021.02.006] [Reference Citation Analysis]
303 Meaney CJ, Karas S, Robinson B, Gaesser J, Forrest A, Krzyzanski W, Panesar M, Rao GG. Definition and Validation of a Novel Metric of Erythropoiesis-Stimulating Agent Response in Hemodialysis Patients. J Clin Pharmacol 2019;59:418-26. [PMID: 30412269 DOI: 10.1002/jcph.1330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
304 Michels WM, Jaar BG, Ephraim PL, Liu Y, Miskulin DC, Tangri N, Crews DC, Scialla JJ, Shafi T, Sozio SM, Bandeen-Roche K, Cook CJ, Meyer KB, Boulware LE; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators. Intravenous iron administration strategies and anemia management in hemodialysis patients. Nephrol Dial Transplant 2017;32:173-81. [PMID: 27604984 DOI: 10.1093/ndt/gfw316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
305 Musio F. Revisiting the treatment of anemia in the setting of chronic kidney disease, hematologic malignancies, and cancer: perspectives with opinion and commentary. Expert Rev Hematol 2020;13:1175-88. [PMID: 33028115 DOI: 10.1080/17474086.2020.1830371] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
306 Xu Y, Evans M, Barany P, James G, Sjölander A, Carrero JJ. Factors affecting pre-end-stage kidney disease haemoglobin control and outcomes following dialysis initiation: a nationwide study. Clin Kidney J 2021;14:1780-8. [PMID: 34221385 DOI: 10.1093/ckj/sfaa213] [Reference Citation Analysis]
307 Staibano P, Perelman I, Lombardi J, Davis A, Tinmouth A, Carrier M, Stevenson C, Saidenberg E. Patient-Centred Outcomes in Anaemia and Renal Disease: A Systematic Review. Kidney Dis (Basel) 2020;6:74-84. [PMID: 32309289 DOI: 10.1159/000502208] [Reference Citation Analysis]
308 Slotki I, Cabantchik ZI. The Labile Side of Iron Supplementation in CKD. J Am Soc Nephrol 2015;26:2612-9. [PMID: 25999405 DOI: 10.1681/ASN.2015010052] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
309 Suresh S, Wright EC, Wright DG, Abbott KC, Noguchi CT. Erythropoietin treatment and the risk of hip fractures in hemodialysis patients. J Bone Miner Res 2021;36:1211-9. [PMID: 33949002 DOI: 10.1002/jbmr.4297] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
310 Foley RN, Curtis BM, Parfrey PS. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. Clin J Am Soc Nephrol 2008;3:1669-75. [PMID: 18922988 DOI: 10.2215/CJN.02100508] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
311 Kessler M, Landais P, Bataille P, Yver L, Koné S, Kraemer S, Brillet G, Canivet E. [Anemia management in French hemodialysis patients: DiaNE study results at 3 years (DiaNE2)]. Nephrol Ther 2011;7:182-7. [PMID: 21227765 DOI: 10.1016/j.nephro.2010.11.006] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
312 Ishani A, Guo H, Arneson TJ, Gilbertson DT, Mau LW, Li S, Dunning S, Collins AJ. Possible effects of the new Medicare reimbursement policy on African Americans with ESRD. J Am Soc Nephrol 2009;20:1607-13. [PMID: 19389846 DOI: 10.1681/ASN.2008080853] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
313 Chang WX, Asakawa S, Toyoki D, Nemoto Y, Morimoto C, Tamura Y, Ota T, Shibata S, Fujigaki Y, Shen ZY, Uchida S. Predictors and the Subsequent Risk of End-Stage Renal Disease - Usefulness of 30% Decline in Estimated GFR over 2 Years. PLoS One 2015;10:e0132927. [PMID: 26177463 DOI: 10.1371/journal.pone.0132927] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
314 Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:386-93. [PMID: 19176796 DOI: 10.2215/CJN.02840608] [Cited by in Crossref: 124] [Cited by in F6Publishing: 65] [Article Influence: 9.5] [Reference Citation Analysis]
315 Erez D, Shefler C, Roitman E, Levy S, Dovrish Z, Ellis M, Twito O. Anemia in Diabetes and Pre-Diabetes with Normal Kidney Function: Prevalence and Clinical Outcomes. Endocr Pract 2021:S1530-891X(21)01290-8. [PMID: 34742906 DOI: 10.1016/j.eprac.2021.10.005] [Reference Citation Analysis]
316 Bennett CL, Spiegel DM, Macdougall IC, Norris L, Qureshi ZP, Sartor O, Lai SY, Tallman MS, Raisch DW, Smith SW. A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR). Semin Thromb Hemost. 2012;38:783-796. [PMID: 23111861 DOI: 10.1055/s-0032-1328884] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
317 Schaefer B, Wühl E. Educational paper: Progression in chronic kidney disease and prevention strategies. Eur J Pediatr 2012;171:1579-88. [PMID: 22968936 DOI: 10.1007/s00431-012-1814-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
318 Panwar B, Judd SE, Warnock DG, McClellan WM, Booth JN 3rd, Muntner P, Gutiérrez OM. Hemoglobin Concentration and Risk of Incident Stroke in Community-Living Adults. Stroke 2016;47:2017-24. [PMID: 27382006 DOI: 10.1161/STROKEAHA.116.013077] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
319 Suresh S, Rajvanshi PK, Noguchi CT. The Many Facets of Erythropoietin Physiologic and Metabolic Response. Front Physiol 2019;10:1534. [PMID: 32038269 DOI: 10.3389/fphys.2019.01534] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 15.0] [Reference Citation Analysis]
320 Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver Int 2010;30:240-50. [PMID: 19889081 DOI: 10.1111/j.1478-3231.2009.02156.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 3.7] [Reference Citation Analysis]
321 Hougen I, Collister D, Bourrier M, Ferguson T, Hochheim L, Komenda P, Rigatto C, Tangri N. Safety of Intravenous Iron in Dialysis: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol 2018;13:457-67. [PMID: 29463597 DOI: 10.2215/CJN.05390517] [Cited by in Crossref: 38] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
322 Agarwal R, Davis JL, Smith L. Serum albumin is strongly associated with erythropoietin sensitivity in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:98-104. [PMID: 18045859 DOI: 10.2215/CJN.03330807] [Cited by in Crossref: 42] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
323 Sun P, Jia J, Fan F, Zhao J, Huo Y, Ganesh SK, Zhang Y. Hemoglobin and erythrocyte count are independently and positively associated with arterial stiffness in a community-based study. J Hum Hypertens 2021;35:265-73. [PMID: 32265488 DOI: 10.1038/s41371-020-0332-6] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
324 Song HY, Wei CM, Zhou WX, Hu HF, Wan QJ. Association between admission hemoglobin level and prognosis in patients with type 2 diabetes mellitus. World J Diabetes 2021; 12(11): 1917-1927 [PMID: 34888016 DOI: 10.4239/wjd.v12.i11.1917] [Reference Citation Analysis]
325 Diskin CJ. Towards Erythropoietin Equations That Estimate Oxygen Delivery rather than Static Hemoglobin Targets. Nephron Clin Pract 2012;120:c48-53. [DOI: 10.1159/000334627] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
326 Anderson J, Glynn LG, Newell J, Iglesias AA, Reddan D, Murphy AW. The impact of renal insufficiency and anaemia on survival in patients with cardiovascular disease: a cohort study. BMC Cardiovasc Disord 2009;9:51. [PMID: 19909540 DOI: 10.1186/1471-2261-9-51] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
327 Mehdi U, Toto RD. Anemia, diabetes, and chronic kidney disease. Diabetes Care. 2009;32:1320-1326. [PMID: 19564475 DOI: 10.2337/dc08-0779] [Cited by in Crossref: 89] [Cited by in F6Publishing: 88] [Article Influence: 6.8] [Reference Citation Analysis]
328 Stirnadel-Farrant HA, Luo J, Kler L, Cizman B, Jones D, Brunelli SM, Cobitz AR. Anemia and mortality in patients with nondialysis-dependent chronic kidney disease. BMC Nephrol 2018;19:135. [PMID: 29890958 DOI: 10.1186/s12882-018-0925-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
329 Lye WK, Paterson E, Patterson CC, Maxwell AP, Binte Mohammed Abdul RB, Tai ES, Cheng CY, Kayama T, Yamashita H, Sarnak M, Shlipak M, Matsushita K, Mutlu U, Ikram MA, Klaver C, Kifley A, Mitchell P, Myers C, Klein BE, Klein R, Wong TY, Sabanayagam C, McKay GJ. A systematic review and participant-level meta-analysis found little association of retinal microvascular caliber with reduced kidney function. Kidney Int 2021;99:696-706. [PMID: 32810524 DOI: 10.1016/j.kint.2020.06.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
330 Nakanishi T, Kuragano T, Kaibe S, Nagasawa Y, Hasuike Y. Should we reconsider iron administration based on prevailing ferritin and hepcidin concentrations? Clin Exp Nephrol 2012;16:819-26. [PMID: 23053592 DOI: 10.1007/s10157-012-0694-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
331 Winkelmayer WC, Liu J, Chertow GM, Tamura MK. Predialysis nephrology care of older patients approaching end-stage renal disease. Arch Intern Med. 2011;171:1371-1378. [PMID: 21824952 DOI: 10.1001/archinternmed.2011.360] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
332 Fell LH, Seiler-Mußler S, Sellier AB, Rotter B, Winter P, Sester M, Fliser D, Heine GH, Zawada AM. Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells. Nephrol Dial Transplant 2016;31:1835-45. [PMID: 27190361 DOI: 10.1093/ndt/gfw045] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
333 Winkelmayer WC, Mitani AA, Goldstein BA, Brookhart MA, Chertow GM. Trends in anemia care in older patients approaching end-stage renal disease in the United States (1995-2010). JAMA Intern Med 2014;174:699-707. [PMID: 24589911 DOI: 10.1001/jamainternmed.2014.87] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
334 Kovesdy CP, Kalantar-Zadeh K. Why is protein-energy wasting associated with mortality in chronic kidney disease? Semin Nephrol. 2009;29:3-14. [PMID: 19121469 DOI: 10.1016/j.semnephrol.2008.10.002] [Cited by in Crossref: 133] [Cited by in F6Publishing: 111] [Article Influence: 10.2] [Reference Citation Analysis]
335 Davis-Ajami ML, Wu J, Downton K, Ludeman E, Noxon V. Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility. Biologics 2014;8:155-67. [PMID: 24790409 DOI: 10.2147/BTT.S27578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
336 Minamishima YA, Moslehi J, Bardeesy N, Cullen D, Bronson RT, Kaelin WG Jr. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 2008;111:3236-44. [PMID: 18096761 DOI: 10.1182/blood-2007-10-117812] [Cited by in Crossref: 200] [Cited by in F6Publishing: 194] [Article Influence: 13.3] [Reference Citation Analysis]
337 He J, Shlipak M, Anderson A, Roy JA, Feldman HI, Kallem RR, Kanthety R, Kusek JW, Ojo A, Rahman M, Ricardo AC, Soliman EZ, Wolf M, Zhang X, Raj D, Hamm L; CRIC (Chronic Renal Insufficiency Cohort) Investigators. Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study. J Am Heart Assoc 2017;6:e005336. [PMID: 28515118 DOI: 10.1161/JAHA.116.005336] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 6.2] [Reference Citation Analysis]
338 Lacquaniti A, Pasqualetti P, Tocco TCD, Campo S, Rovito S, Bucca M, Ragusa A, Monardo P. Ferric carboxymaltose versus ferric gluconate in hemodialysis patients: Reduction of erythropoietin dose in 4 years of follow-up. Kidney Res Clin Pract 2020;39:334-43. [PMID: 32839355 DOI: 10.23876/j.krcp.20.015] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
339 Virani SA, Khosla A, Levin A. Chronic kidney disease, heart failure and anemia. Can J Cardiol 2008;24 Suppl B:22B-4B. [PMID: 18629385 DOI: 10.1016/s0828-282x(08)71026-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
340 Schmidt RE, Green KG, Feng D, Dorsey DA, Parvin CA, Lee JM, Xiao Q, Brines M. Erythropoietin and its carbamylated derivative prevent the development of experimental diabetic autonomic neuropathy in STZ-induced diabetic NOD-SCID mice. Exp Neurol 2008;209:161-70. [PMID: 17967455 DOI: 10.1016/j.expneurol.2007.09.018] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.9] [Reference Citation Analysis]
341 Frimat L. [Transfusion requirements in chronic kidney disease]. Transfus Clin Biol 2008;15:214-6. [PMID: 18938100 DOI: 10.1016/j.tracli.2008.09.006] [Reference Citation Analysis]
342 Cravedi P, Manrique J, Hanlon KE, Reid-Adam J, Brody J, Prathuangsuk P, Mehrotra A, Heeger PS. Immunosuppressive effects of erythropoietin on human alloreactive T cells. J Am Soc Nephrol 2014;25:2003-15. [PMID: 24676641 DOI: 10.1681/ASN.2013090945] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
343 Wetmore JB, Tzivelekis S, Collins AJ, Solid CA. Effects of the prospective payment system on anemia management in maintenance dialysis patients: implications for cost and site of care. BMC Nephrol 2016;17:53. [PMID: 27228981 DOI: 10.1186/s12882-016-0267-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
344 Locatelli F, Hannedouche T, Fishbane S, Morgan Z, Oguey D, White WB. Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial. Clin J Am Soc Nephrol 2019;14:1701-10. [PMID: 31420350 DOI: 10.2215/CJN.01380219] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
345 Massy ZA, Drueke TB. The evolving science of anemia management in chronic kidney disease. Kidney Int Suppl (2011) 2021;11:1-2. [PMID: 33777491 DOI: 10.1016/j.kisu.2020.11.002] [Reference Citation Analysis]
346 Andreucci M, Fuiano G, Presta P, Lucisano G, Leone F, Fuiano L, Bisesti V, Esposito P, Russo D, Memoli B. Downregulation of cell survival signalling pathways and increased cell damage in hydrogen peroxide-treated human renal proximal tubular cells by alpha-erythropoietin. Cell Prolif. 2009;42:554-561. [PMID: 19508320 DOI: 10.1111/j.1365-2184.2009.00617.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 39] [Article Influence: 2.3] [Reference Citation Analysis]
347 Hirata M, Tashiro Y, Aizawa K, Kawasaki R, Shimonaka Y, Endo K. Epoetin beta pegol alleviates oxidative stress and exacerbation of renal damage from iron deposition, thereby delaying CKD progression in progressive glomerulonephritis rats. Physiol Rep 2015;3:e12637. [PMID: 26634903 DOI: 10.14814/phy2.12637] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
348 Suttorp MM, Hoekstra T, Mittelman M, Ott I, Franssen CF, Dekker FW. Effect of erythropoiesis-stimulating agents on blood pressure in pre-dialysis patients. PLoS One 2013;8:e84848. [PMID: 24391978 DOI: 10.1371/journal.pone.0084848] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
349 Woo M, Hawkins M. Beyond erythropoiesis: emerging metabolic roles of erythropoietin. Diabetes 2014;63:2229-31. [PMID: 24962925 DOI: 10.2337/db14-0566] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
350 Khankin EV, Mutter WP, Tamez H, Yuan HT, Karumanchi SA, Thadhani R. Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease. PLoS One 2010;5:e9246. [PMID: 20169072 DOI: 10.1371/journal.pone.0009246] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
351 Carrera F, Burnier M. Use of darbepoetin alfa in the treatment of anaemia of chronic kidney disease: clinical and pharmacoeconomic considerations. NDT Plus 2009;2:i9-i17. [PMID: 19461859 DOI: 10.1093/ndtplus/sfn175] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
352 Sijpkens YW, Berkhout-Byrne NC, Rabelink TJ. Optimal predialysis care. NDT Plus 2008;1:iv7-iv13. [PMID: 25983991 DOI: 10.1093/ndtplus/sfn117] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
353 Calvo JA, Miskulin DC, Meyer KB, Weiner DE. Nadir hemoglobin levels after discontinuation of epoetin in hemodialysis patients. Clin J Am Soc Nephrol 2010;5:1621-7. [PMID: 20651155 DOI: 10.2215/CJN.02650310] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
354 Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJ. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008;19:1599-605. [PMID: 18525001 DOI: 10.1681/ASN.2007101156] [Cited by in Crossref: 175] [Cited by in F6Publishing: 82] [Article Influence: 12.5] [Reference Citation Analysis]
355 Cappell KA, Shreay S, Cao Z, Varker HV, Paoli CJ, Gitlin M. Red blood cell (RBC) transfusion rates among US chronic dialysis patients during changes to Medicare end-stage renal disease (ESRD) reimbursement systems and erythropoiesis stimulating agent (ESA) labels. BMC Nephrol 2014;15:116. [PMID: 25015348 DOI: 10.1186/1471-2369-15-116] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
356 Galle JC, Claes K, Kiss I, Winearls CG, Herlitz H, Guerin A, Di Giulio S, Suranyi MG, Bridges I, Addison J, Farouk M. An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study. Nephrol Dial Transplant 2012;27:2303-11. [PMID: 22140136 DOI: 10.1093/ndt/gfr677] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
357 Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol. 2008;3:505-521. [PMID: 18184879 DOI: 10.2215/cjn.03670807] [Cited by in Crossref: 351] [Cited by in F6Publishing: 166] [Article Influence: 25.1] [Reference Citation Analysis]
358 Kiss Z, Kulcsár I, Kiss I. [Hemoglobin variability in chronic renal failure patients]. Orv Hetil 2008;149:1925-34. [PMID: 18842510 DOI: 10.1556/OH.2008.28471] [Reference Citation Analysis]
359 Parkash O, Iqbal R, Jafri F, Azam I, Jafri W. Frequency of poor quality of life and predictors of health related quality of life in cirrhosis at a tertiary care hospital Pakistan. BMC Res Notes 2012;5:446. [PMID: 22905795 DOI: 10.1186/1756-0500-5-446] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
360 Patel MS, Carson JL. Anemia in the preoperative patient. Med Clin North Am 2009;93:1095-104. [PMID: 19665622 DOI: 10.1016/j.mcna.2009.05.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
361 Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 2008;3:133-8. [PMID: 18045862 DOI: 10.2215/CJN.01610407] [Cited by in Crossref: 127] [Cited by in F6Publishing: 43] [Article Influence: 8.5] [Reference Citation Analysis]
362 Del Vecchio L, Minutolo R. ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia? J Clin Med 2021;10:839. [PMID: 33670704 DOI: 10.3390/jcm10040839] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
363 McMahon LP, Cai MX, Baweja S, Holt SG, Kent AB, Perkovic V, Leikis MJ, Becker GJ. Mortality in dialysis patients may not be associated with ESA dose: a 2-year prospective observational study. BMC Nephrol 2012;13:40. [PMID: 22702540 DOI: 10.1186/1471-2369-13-40] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
364 Tonks A. Too much of a good thing. BMJ 2007;334:978-80. [PMID: 17494015 DOI: 10.1136/bmj.39198.510347.AD] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
365 Toblli JE, Di Gennaro F. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status. PLoS One 2015;10:e0125528. [PMID: 25928811 DOI: 10.1371/journal.pone.0125528] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
366 Yarnoff BO, Hoerger TJ, Simpson SA, Pavkov ME, Burrows NR, Shrestha SS, Williams DE, Zhuo X. The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease. PLoS One 2016;11:e0157323. [PMID: 27404556 DOI: 10.1371/journal.pone.0157323] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
367 Kovesdy CP, Kalantar-Zadeh K. Observational studies versus randomized controlled trials: avenues to causal inference in nephrology. Adv Chronic Kidney Dis 2012;19:11-8. [PMID: 22364796 DOI: 10.1053/j.ackd.2011.09.004] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 4.1] [Reference Citation Analysis]
368 Antić A, Stanojković Z. [Red blood cells transfusions in oncological patients treated with radio- and chemotherapy]. Vojnosanit Pregl 2011;68:28-34. [PMID: 21425615 DOI: 10.2298/vsp1101028a] [Reference Citation Analysis]
369 Covic A, Jackson J, Hadfield A, Pike J, Siriopol D. Real-World Impact of Cardiovascular Disease and Anemia on Quality of Life and Productivity in Patients with Non-Dialysis-Dependent Chronic Kidney Disease. Adv Ther 2017;34:1662-72. [PMID: 28578500 DOI: 10.1007/s12325-017-0566-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
370 Baek SY, Chung HJ, Kim KW, Cho KH, Choi I, Lee HT. Potential use of transgenic domestic pigs expressing recombinant human erythropoietin in diabetes translation research. Anim Cells Syst (Seoul) 2019;23:42-9. [PMID: 30834158 DOI: 10.1080/19768354.2018.1554544] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
371 Hayashi T, Kimura T, Yasuda K, Obi Y, Sasaki K, Iio K, Miyasato K, Kamimura T, Kitamura H, Tsubakihara Y, Rakugi H, Isaka Y. Prognostic significance of left ventricular hypertrophy observed at dialysis initiation depends on the pre-dialysis use of erythropoiesis-stimulating agents. Clin Exp Nephrol 2013;17:294-303. [PMID: 23100176 DOI: 10.1007/s10157-012-0705-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
372 Lim SK, Goh BL, Visvanathan R, Kim SH, Jeon JS, Kim SG, Chang JH, Lim CS, Morad Z. A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-alpha) vs. Eprex® in patients with anaemia of chronic renal failure. BMC Nephrol 2021;22:391. [PMID: 34823497 DOI: 10.1186/s12882-021-02601-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
373 Ishii T, Tanaka T, Nangaku M. Profile of Daprodustat in the Treatment of Renal Anemia Due to Chronic Kidney Disease. Ther Clin Risk Manag 2021;17:155-63. [PMID: 33628028 DOI: 10.2147/TCRM.S293879] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
374 Foley RN. Erythropoietin: physiology and molecular mechanisms. Heart Fail Rev 2008;13:405-14. [PMID: 18236154 DOI: 10.1007/s10741-008-9083-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
375 Guedes M, Guetter CR, Erbano LHO, Palone AG, Zee J, Robinson BM, Pisoni R, de Moraes TP, Pecoits-Filho R, Baena CP. Physical health-related quality of life at higher achieved hemoglobin levels among chronic kidney disease patients: a systematic review and meta-analysis. BMC Nephrol 2020;21:259. [PMID: 32641153 DOI: 10.1186/s12882-020-01912-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
376 Estrella MM, Jaar BG, Cavanaugh KL, Fox CH, Perazella MA, Soman SS, Howell E, Rocco MV, Choi MJ. Perceptions and use of the national kidney foundation KDOQI guidelines: a survey of U.S. renal healthcare providers. BMC Nephrol. 2013;14:230. [PMID: 24152744 DOI: 10.1186/1471-2369-14-230] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
377 House AA, Haapio M, Lassus J, Bellomo R, Ronco C. Pharmacological management of cardiorenal syndromes. Int J Nephrol 2011;2011:630809. [PMID: 21660311 DOI: 10.4061/2011/630809] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
378 Silver MR, Geronemus R, Krause M, Chen CY, Kewalramani R, Stehman-Breen C. Anemia treatment with Q2W darbepoetin alfa in patients with chronic kidney disease naïve to erythropoiesis-stimulating agents. Curr Med Res Opin 2009;25:123-31. [PMID: 19210145 DOI: 10.1185/03007990802594818] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
379 St Peter WL, Guo H, Kabadi S, Gilbertson DT, Peng Y, Pendergraft T, Li S. Prevalence, treatment patterns, and healthcare resource utilization in Medicare and commercially insured non-dialysis-dependent chronic kidney disease patients with and without anemia in the United States. BMC Nephrol 2018;19:67. [PMID: 29544446 DOI: 10.1186/s12882-018-0861-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
380 Huml AM, Sehgal AR. Hemodialysis Quality Metrics in the First Year Following a Failed Kidney Transplant. Am J Nephrol 2019;50:161-7. [PMID: 31311008 DOI: 10.1159/000501605] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
381 Provenzano R, Tumlin J, Zabaneh R, Chou J, Hemmerich S, Neff TB, Yu KP. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients. J Clin Pharmacol 2020;60:1432-40. [PMID: 32603526 DOI: 10.1002/jcph.1648] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
382 Eckardt KU, Kim J, Kronenberg F, Aljama P, Anker SD, Canaud B, Molemans B, Stenvinkel P, Schernthaner G, Ireland E. Hemoglobin variability does not predict mortality in European hemodialysis patients. J Am Soc Nephrol. 2010;21:1765-1775. [PMID: 20798262 DOI: 10.1681/asn.2009101017] [Cited by in Crossref: 42] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
383 Toida T, Iwakiri T, Sato Y, Komatsu H, Kitamura K, Fujimoto S. Relationship between Hemoglobin Levels Corrected by Interdialytic Weight Gain and Mortality in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study. PLoS One 2017;12:e0169117. [PMID: 28046068 DOI: 10.1371/journal.pone.0169117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
384 Mc Causland FR, Claggett B, Burdmann EA, Chertow GM, Cooper ME, Eckardt KU, Ivanovich P, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA. Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). Am J Kidney Dis 2019;73:309-15. [PMID: 30578152 DOI: 10.1053/j.ajkd.2018.10.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
385 Freburger JK, Ellis AR, Kshirsagar AV, Wang L, Brookhart MA. Comparative short-term safety of bolus versus maintenance iron dosing in hemodialysis patients: a replication study. BMC Nephrol 2014;15:154. [PMID: 25245951 DOI: 10.1186/1471-2369-15-154] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
386 Zheng Q, Wang Y, Yang H, Sun L, Fu X, Wei R, Liu YN, Liu WJ. Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. Front Pharmacol 2020;11:573645. [PMID: 33597868 DOI: 10.3389/fphar.2020.573645] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
387 Strippoli GF; Clinical Evaluation of the DOse of Erythropoietins Study Group (C.E. DOSE). Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol. Trials 2010;11:70. [PMID: 20534124 DOI: 10.1186/1745-6215-11-70] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
388 Ruifrok WP, Lipsic E, de Boer RA, van Gilst WH, van Veldhuisen DJ. Erythropoiesis stimulation in acute ischemic syndromes. Heart Fail Clin 2010;6:313-21. [PMID: 20630406 DOI: 10.1016/j.hfc.2009.12.002] [Reference Citation Analysis]
389 Fuller DS, Bieber BA, Pisoni RL, Li Y, Morgenstern H, Akizawa T, Jacobson SH, Locatelli F, Port FK, Robinson BM. International Comparisons to Assess Effects of Payment and Regulatory Changes in the United States on Anemia Practice in Patients on Hemodialysis: The Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol 2016;27:2205-15. [PMID: 26582402 DOI: 10.1681/ASN.2015060673] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
390 Cho YI, Cho DJ. Hemorheology and microvascular disorders. Korean Circ J 2011;41:287-95. [PMID: 21779279 DOI: 10.4070/kcj.2011.41.6.287] [Cited by in Crossref: 61] [Cited by in F6Publishing: 46] [Article Influence: 5.5] [Reference Citation Analysis]
391 Conway B, Fried L, Orchard T. Hemoglobin and overt nephropathy complications in type 1 diabetes. Ann Epidemiol 2008;18:147-55. [PMID: 18083536 DOI: 10.1016/j.annepidem.2007.07.110] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
392 Chen N, Qian J, Chen J, Yu X, Mei C, Hao C, Jiang G, Lin H, Zhang X, Zuo L, He Q, Fu P, Li X, Ni D, Hemmerich S, Liu C, Szczech L, Besarab A, Neff TB, Peony Yu KH, Valone FH. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant. 2017;32:1373-1386. [PMID: 28371815 DOI: 10.1093/ndt/gfx011] [Cited by in Crossref: 93] [Cited by in F6Publishing: 90] [Article Influence: 23.3] [Reference Citation Analysis]
393 Streja E, Park J, Chan TY, Lee J, Soohoo M, Rhee CM, Arah OA, Kalantar-Zadeh K. Erythropoietin Dose and Mortality in Hemodialysis Patients: Marginal Structural Model to Examine Causality. Int J Nephrol 2016;2016:6087134. [PMID: 27298736 DOI: 10.1155/2016/6087134] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
394 Conway BN, Miller RG, Klein R, Orchard TJ. Prediction of proliferative diabetic retinopathy with hemoglobin level. Arch Ophthalmol 2009;127:1494-9. [PMID: 19901215 DOI: 10.1001/archophthalmol.2009.274] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
395 Lestz RM, Fivush BA, Atkinson MA. Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis. Pediatr Nephrol 2014;29:2021-8. [PMID: 24794833 DOI: 10.1007/s00467-014-2820-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
396 Valliant A, Hofmann RM. Managing dialysis patients who develop anemia caused by chronic kidney disease: focus on peginesatide. Int J Nanomedicine 2013;8:3297-307. [PMID: 24023516 DOI: 10.2147/IJN.S44944] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
397 Drozdz M, Weigert A, Silva F, Frazão J, Alsuwaida A, Krishnan M, Kleophas W, Brzosko S, Johansson FK, Jacobson SH. Achievement of renal anemia KDIGO targets by two different clinical strategies - a European hemodialysis multicenter analysis. BMC Nephrol 2019;20:5. [PMID: 30616548 DOI: 10.1186/s12882-018-1196-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
398 Thilly N, Stengel B, Boini S, Villar E, Couchoud C, Frimat L. Evaluation and determinants of underprescription of erythropoiesis stimulating agents in pre-dialysis patients with anaemia. Nephron Clin Pract 2008;108:c67-74. [PMID: 18182782 DOI: 10.1159/000112914] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
399 Sheetz M, Barrington P, Callies S, Berg PH, McColm J, Marbury T, Decker B, Dyas GL, Truhlar SME, Benschop R, Leung D, Berg J, Witcher DR. Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease. Br J Clin Pharmacol 2019;85:935-48. [PMID: 30677788 DOI: 10.1111/bcp.13877] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
400 Jung MY, Hwang SY, Hong YA, Oh SY, Seo JH, Lee YM, Park SW, Kim JS, Wang JK, Kim JY, Lee JE, Ko GJ, Pyo HJ, Kwon YJ. Optimal hemoglobin level for anemia treatment in a cohort of hemodialysis patients. Kidney Res Clin Pract 2015;34:20-7. [PMID: 26484015 DOI: 10.1016/j.krcp.2014.11.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
401 Holdstock L, Meadowcroft AM, Maier R, Johnson BM, Jones D, Rastogi A, Zeig S, Lepore JJ, Cobitz AR. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. J Am Soc Nephrol 2016;27:1234-44. [PMID: 26494831 DOI: 10.1681/ASN.2014111139] [Cited by in Crossref: 100] [Cited by in F6Publishing: 47] [Article Influence: 14.3] [Reference Citation Analysis]
402 Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93:914-919. [PMID: 18160461 DOI: 10.1210/jc.2007-1692] [Cited by in Crossref: 200] [Cited by in F6Publishing: 177] [Article Influence: 13.3] [Reference Citation Analysis]
403 Wühl E, Schaefer F. Therapeutic strategies to slow chronic kidney disease progression. Pediatr Nephrol. 2008;23:705-716. [PMID: 18335252 DOI: 10.1007/s00467-008-0789-y] [Cited by in Crossref: 56] [Cited by in F6Publishing: 40] [Article Influence: 4.0] [Reference Citation Analysis]
404 Herrington W, Haynes R, Staplin N, Emberson J, Baigent C, Landray M. Evidence for the prevention and treatment of stroke in dialysis patients. Semin Dial 2015;28:35-47. [PMID: 25040468 DOI: 10.1111/sdi.12281] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
405 Savona MR, Silver SM. Erythropoietin-Stimulating Agents in Oncology. The Cancer Journal 2008;14:75-84. [DOI: 10.1097/ppo.0b013e31816a5f51] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
406 Duong U, Kalantar-Zadeh K, Molnar MZ, Zaritsky JJ, Teitelbaum I, Kovesdy CP, Mehrotra R. Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients. Am J Nephrol 2012;35:198-208. [PMID: 22286821 DOI: 10.1159/000335685] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
407 Winterberg PD, Robertson JM, Kelleman MS, George RP, Ford ML. T Cells Play a Causal Role in Diastolic Dysfunction during Uremic Cardiomyopathy. J Am Soc Nephrol 2019:ASN. [PMID: 30728178 DOI: 10.1681/ASN.2017101138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
408 . Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. Kidney Int Suppl (2011) 2013;3:91-111. [PMID: 25599000 DOI: 10.1038/kisup.2012.67] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
409 Lau BC, Ong KY, Yap CW, Vathsala A, How P. Predictors of anemia in a multi-ethnic chronic kidney disease population: a case-control study. Springerplus 2015;4:233. [PMID: 26155438 DOI: 10.1186/s40064-015-1001-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
410 Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, Villa G, Van Vlem B, McMahon AW, Kerloëguen C, Beyer U; STRIATA Study Investigators. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study. Nephrol Dial Transplant 2008;23:3654-61. [PMID: 18586762 DOI: 10.1093/ndt/gfn320] [Cited by in Crossref: 55] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
411 Ryu JH, Koo TY, Ro H, Cho JH, Kim MG, Huh KH, Park JB, Lee S, Han S, Kim J, Oh KH, Yang J; KNOW-KT Study group. Better health-related quality of life in kidney transplant patients compared to chronic kidney disease patients with similar renal function. PLoS One 2021;16:e0257981. [PMID: 34606505 DOI: 10.1371/journal.pone.0257981] [Reference Citation Analysis]
412 Ginsberg JS, Zhan M, Diamantidis CJ, Woods C, Chen J, Fink JC. Patient-reported and actionable safety events in CKD. J Am Soc Nephrol 2014;25:1564-73. [PMID: 24556352 DOI: 10.1681/ASN.2013090921] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
413 Eckardt KU, Scherhag A, Macdougall IC, Tsakiris D, Clyne N, Locatelli F, Zaug MF, Burger HU, Drueke TB. Left ventricular geometry predicts cardiovascular outcomes associated with anemia correction in CKD. J Am Soc Nephrol 2009;20:2651-60. [PMID: 19850955 DOI: 10.1681/ASN.2009060631] [Cited by in Crossref: 81] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
414 Stoian I, Manolescu B, Atanasiu V, Lupescu O. New alternatives for erythropoietin therapy in chronic renal failure. Open Medicine 2007;2:361-78. [DOI: 10.2478/s11536-007-0038-y] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
415 Lippold S, Thavarajah R, Reusch D, Wuhrer M, Nicolardi S. Glycoform analysis of intact erythropoietin by MALDI FT-ICR mass spectrometry. Anal Chim Acta 2021;1185:339084. [PMID: 34711323 DOI: 10.1016/j.aca.2021.339084] [Reference Citation Analysis]
416 Wetmore JB, Rigler SK, Mahnken JD, Mukhopadhyay P, Shireman TI. Considering health insurance: how do dialysis initiates with Medicaid coverage differ from persons without Medicaid coverage? Nephrol Dial Transplant 2010;25:198-205. [PMID: 19736241 DOI: 10.1093/ndt/gfp396] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
417 Elliott S, Tomita D, Endre Z. Erythropoiesis stimulating agents and reno-protection: a meta-analysis. BMC Nephrol 2017;18:14. [PMID: 28077085 DOI: 10.1186/s12882-017-0438-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
418 Yamamoto H, Taguchi M, Matsuda Y, Iekushi K, Yamada T, Akizawa T. Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies. BMJ Open 2019;9:e026704. [PMID: 31203242 DOI: 10.1136/bmjopen-2018-026704] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
419 Shah BN, Greaves K. The cardiorenal syndrome: a review. Int J Nephrol 2010;2011:920195. [PMID: 21253529 DOI: 10.4061/2011/920195] [Cited by in Crossref: 12] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
420 Jhamb M, Weisbord SD, Steel JL, Unruh M. Fatigue in patients receiving maintenance dialysis: a review of definitions, measures, and contributing factors. Am J Kidney Dis. 2008;52:353-365. [PMID: 18572290 DOI: 10.1053/j.ajkd.2008.05.005] [Cited by in Crossref: 141] [Cited by in F6Publishing: 133] [Article Influence: 10.1] [Reference Citation Analysis]
421 Miskulin DC, Zhou J, Tangri N, Bandeen-Roche K, Cook C, Ephraim PL, Crews DC, Scialla JJ, Sozio SM, Shafi T, Jaar BG, Boulware LE; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators. Trends in anemia management in US hemodialysis patients 2004-2010. BMC Nephrol 2013;14:264. [PMID: 24289058 DOI: 10.1186/1471-2369-14-264] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
422 Jablonski KL, Chonchol M. Recent advances in the management of hemodialysis patients: a focus on cardiovascular disease. F1000Prime Rep 2014;6:72. [PMID: 25165571 DOI: 10.12703/P6-72] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
423 Wong CJ, Moxey-Mims M, Jerry-Fluker J, Warady BA, Furth SL. CKiD (CKD in children) prospective cohort study: a review of current findings. Am J Kidney Dis 2012;60:1002-11. [PMID: 23022429 DOI: 10.1053/j.ajkd.2012.07.018] [Cited by in Crossref: 138] [Cited by in F6Publishing: 97] [Article Influence: 13.8] [Reference Citation Analysis]
424 Novak JE, Inrig JK, Patel UD, Califf RM, Szczech LA. Negative trials in nephrology: what can we learn? Kidney Int 2008;74:1121-7. [PMID: 18563051 DOI: 10.1038/ki.2008.286] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
425 Vanholder R, Abramowicz D, Cannata-Andia JB, Cocchi V, Cochat P, Covic A, Eckardt KU, Fouque D, Heimburger O, Jenkins S, MacLeod A, Lindley E, Locatelli F, London G, Marti I Monros A, Spasovski G, Tattersall J, Van Biesen W, Wanner C, Wiecek A, Zoccali C. The future of European Nephrology 'Guidelines'-a declaration of intent by European Renal Best Practice (ERBP). NDT Plus 2009;2:213-21. [PMID: 25983994 DOI: 10.1093/ndtplus/sfp035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
426 Paschos N, Lykissas MG, Beris AE. The role of erythropoietin as an inhibitor of tissue ischemia. Int J Biol Sci 2008;4:161-8. [PMID: 18566695 DOI: 10.7150/ijbs.4.161] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
427 Bhandari S. A hospital-based cost minimization study of the potential financial impact on the UK health care system of introduction of iron isomaltoside 1000. Ther Clin Risk Manag 2011;7:103-13. [PMID: 21479141 DOI: 10.2147/TCRM.S17536] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
428 Wang B, Yin Q, Han YC, Wu M, Li ZL, Tu Y, Zhou LT, Wei Q, Liu H, Tang RN, Cao JY, Lv LL, Liu BC. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients. Ren Fail 2020;42:912-25. [PMID: 32869703 DOI: 10.1080/0886022X.2020.1811121] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
429 Levin A, Hemmelgarn B, Culleton B, Tobe S, McFarlane P, Ruzicka M, Burns K, Manns B, White C, Madore F. Guidelines for the management of chronic kidney disease. CMAJ. 2008;179:1154-1162. [PMID: 19015566 DOI: 10.1503/cmaj.080351] [Cited by in Crossref: 199] [Cited by in F6Publishing: 179] [Article Influence: 15.3] [Reference Citation Analysis]
430 Al-Ageel NA, Al-Aqeel SA, Abanmy NO, Alwakeel JS, Sabry A, Alsaran KA. Appropriateness of anemia management in hemodialysis patients. Saudi Pharm J 2012;20:85-91. [PMID: 23960781 DOI: 10.1016/j.jsps.2011.08.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
431 Rucker D, Tonelli M. Cardiovascular risk and management in chronic kidney disease. Nat Rev Nephrol 2009;5:287-96. [PMID: 19384330 DOI: 10.1038/nrneph.2009.42] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 3.2] [Reference Citation Analysis]
432 Murphy F, Bennett L, Jenkins K. Managing anaemia of chronic kidney disease. Br J Nurs 2010;19:1281-2, 1284-6. [PMID: 21072014 DOI: 10.12968/bjon.2010.19.20.79681] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
433 Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA. Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS One 2013;8:e78930. [PMID: 24223866 DOI: 10.1371/journal.pone.0078930] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
434 Kainz A, Mayer B, Kramar R, Oberbauer R. Association of ESA hypo-responsiveness and haemoglobin variability with mortality in haemodialysis patients. Nephrol Dial Transplant 2010;25:3701-6. [PMID: 20507852 DOI: 10.1093/ndt/gfq287] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
435 Von Kohorn I, Ehrenkranz RA. Anemia in the preterm infant: erythropoietin versus erythrocyte transfusion--it's not that simple. Clin Perinatol 2009;36:111-23. [PMID: 19161869 DOI: 10.1016/j.clp.2008.09.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
436 Summers S, Holdsworth S, Sharples E. The (re)challenging question of erythropoiesis-stimulating agents inducing pure red cell aplasia. Nephrol Dial Transplant 2008;23:3053-5. [PMID: 18558625 DOI: 10.1093/ndt/gfn326] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
437 Shavit L, Hitti S, Silberman S, Tauber R, Merin O, Lifschitz M, Slotki I, Bitran D, Fink D. Preoperative hemoglobin and outcomes in patients with CKD undergoing cardiac surgery. Clin J Am Soc Nephrol. 2014;9:1536-1544. [PMID: 24993450 DOI: 10.2215/cjn.00110114] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
438 Mehrotra R, Perazella MA, Choi MJ. American Society of Nephrology Quiz and Questionnaire 2014: RRT. Clin J Am Soc Nephrol 2015;10:1100-6. [PMID: 25897000 DOI: 10.2215/CJN.01490215] [Reference Citation Analysis]
439 Harrison LE, Burton JO, Szeto CC, Li PK, McIntyre CW. Endotoxaemia in haemodialysis: a novel factor in erythropoetin resistance? PLoS One 2012;7:e40209. [PMID: 22768256 DOI: 10.1371/journal.pone.0040209] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
440 McQuillan R, Jassal SV. Neuropsychiatric complications of chronic kidney disease. Nat Rev Nephrol 2010;6:471-9. [PMID: 20567247 DOI: 10.1038/nrneph.2010.83] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 3.8] [Reference Citation Analysis]
441 Goodkin DA, Fuller DS, Robinson BM, Combe C, Fluck R, Mendelssohn D, Akizawa T, Pisoni RL, Port FK. Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients. J Am Soc Nephrol 2011;22:358-65. [PMID: 21164028 DOI: 10.1681/ASN.2010020173] [Cited by in Crossref: 42] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
442 Manns BJ, Tonelli M. The new FDA labeling for ESA--implications for patients and providers. Clin J Am Soc Nephrol 2012;7:348-53. [PMID: 22266575 DOI: 10.2215/CJN.09960911] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
443 van Veldhuisen DJ, Anker SD, Ponikowski P, Macdougall IC. Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. Nat Rev Cardiol 2011;8:485-93. [PMID: 21629210 DOI: 10.1038/nrcardio.2011.77] [Cited by in Crossref: 121] [Cited by in F6Publishing: 105] [Article Influence: 11.0] [Reference Citation Analysis]
444 McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, Solomon SD, Tendera M, van Veldhuisen DJ, Albizem M, Cheng S, Scarlata D, Swedberg K, Young JB; RED-HF Committees Investigators. Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). Eur J Heart Fail 2013;15:334-41. [PMID: 23329651 DOI: 10.1093/eurjhf/hfs204] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
445 Moreno López R, Sicilia Aladrén B, Gomollón García F. Use of agents stimulating erythropoiesis in digestive diseases. World J Gastroenterol 2009; 15(37): 4675-4685 [PMID: 19787831 DOI: 10.3748/wjg.15.4675] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
446 Bonato FO, Lemos MM, Cassiolato JL, Canziani ME. Prevalence of ventricular arrhythmia and its associated factors in nondialyzed chronic kidney disease patients. PLoS One 2013;8:e66036. [PMID: 23762460 DOI: 10.1371/journal.pone.0066036] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
447 Evans M, Bower H, Cockburn E, Jacobson SH, Barany P, Carrero JJ. Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: a nationwide analysis. Clin Kidney J 2020;13:821-7. [PMID: 33123358 DOI: 10.1093/ckj/sfaa054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
448 Boshuizen M, Binnekade JM, Nota B, van de Groep K, Cremer OL, Tuinman PR, Horn J, Schultz MJ, van Bruggen R, Juffermans NP; Molecular Diagnosis and Risk Stratification of Sepsis (MARS) Consortium. Iron metabolism in critically ill patients developing anemia of inflammation: a case control study. Ann Intensive Care 2018;8:56. [PMID: 29717382 DOI: 10.1186/s13613-018-0407-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
449 Soni RK, Weisbord SD, Unruh ML. Health-related quality of life outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens 2010;19:153-9. [PMID: 20051850 DOI: 10.1097/MNH.0b013e328335f939] [Cited by in Crossref: 83] [Cited by in F6Publishing: 42] [Article Influence: 6.9] [Reference Citation Analysis]
450 Feteh VF, Choukem SP, Kengne AP, Nebongo DN, Ngowe-Ngowe M. Anemia in type 2 diabetic patients and correlation with kidney function in a tertiary care sub-Saharan African hospital: a cross-sectional study. BMC Nephrol 2016;17:29. [PMID: 26994993 DOI: 10.1186/s12882-016-0247-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
451 Kim T, Rhee CM, Streja E, Obi Y, Brunelli SM, Kovesdy CP, Kalantar-Zadeh K. Longitudinal trends in serum ferritin levels and associated factors in a national incident hemodialysis cohort. Nephrol Dial Transplant 2017;32:370-7. [PMID: 28186572 DOI: 10.1093/ndt/gfw012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
452 Goodnough LT, Schrier SL. Evaluation and management of anemia in the elderly. Am J Hematol 2014;89:88-96. [PMID: 24122955 DOI: 10.1002/ajh.23598] [Cited by in Crossref: 131] [Cited by in F6Publishing: 111] [Article Influence: 16.4] [Reference Citation Analysis]
453 Kapoian T, O’Mara NB, Singh AK, Moran J, Rizkala AR, Geronemus R, Kopelman RC, Dahl NV, Coyne DW. Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin. J Am Soc Nephrol. 2008;19:372-379. [PMID: 18216316 DOI: 10.1681/asn.2007050606] [Cited by in Crossref: 128] [Cited by in F6Publishing: 43] [Article Influence: 9.1] [Reference Citation Analysis]
454 Kalantar-Zadeh K. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology. Am J Nephrol 2017;45:235-47. [PMID: 28142147 DOI: 10.1159/000455387] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 6.4] [Reference Citation Analysis]
455 Schmidt RE, Feng D, Wang Q, Green KG, Snipes LL, Yamin M, Brines M. Effect of insulin and an erythropoietin-derived peptide (ARA290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia. Exp Neurol 2011;232:126-35. [PMID: 21872588 DOI: 10.1016/j.expneurol.2011.05.025] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
456 Block GA, Block MS, Smits G, Mehta R, Isakova T, Wolf M, Chertow GM. A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD. J Am Soc Nephrol 2019;30:1495-504. [PMID: 31278194 DOI: 10.1681/ASN.2018101016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
457 Baglin A, Hanslik T, Prinseau J, Moulonguet-doleris L. Érythropoïétine et insuffisance rénale : jusqu’où ne pas aller ? La Revue de Médecine Interne 2008;29:846-51. [DOI: 10.1016/j.revmed.2007.10.415] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
458 Lee KH, Ho Y, Tarng DC. Iron Therapy in Chronic Kidney Disease: Days of Future Past. Int J Mol Sci 2021;22:1008. [PMID: 33498292 DOI: 10.3390/ijms22031008] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
459 Yang X, Ma RC, So WY, Ko GT, Kong AP, Lam CW, Ho CS, Cockram CS, Wong VC, Tong PC, Chan JC. Impacts of chronic kidney disease and albuminuria on associations between coronary heart disease and its traditional risk factors in type 2 diabetic patients - the Hong Kong diabetes registry. Cardiovasc Diabetol 2007;6:37. [PMID: 18053157 DOI: 10.1186/1475-2840-6-37] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
460 Holdstock L, Cizman B, Meadowcroft AM, Biswas N, Johnson BM, Jones D, Kim SG, Zeig S, Lepore JJ, Cobitz AR. Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease. Clin Kidney J 2019;12:129-38. [PMID: 30746140 DOI: 10.1093/ckj/sfy013] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
461 Schmid H. Cost-effectiveness of continuous erythropoietin receptor activator in anemia. Clinicoecon Outcomes Res 2014;6:319-30. [PMID: 25050070 DOI: 10.2147/CEOR.S46930] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
462 Hörl WH. Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol 2013;9:291-301. [PMID: 23438972 DOI: 10.1038/nrneph.2013.21] [Cited by in Crossref: 66] [Cited by in F6Publishing: 55] [Article Influence: 7.3] [Reference Citation Analysis]
463 Zaki HM, Sliem H, Ibrahim HR, Yassine IA. Neurological Soft Signs in Non-diabetic End Stage Renal Disease Patients: Evaluation and Prediction. Neurol Res 2022;:1-6. [PMID: 35048798 DOI: 10.1080/01616412.2022.2028958] [Reference Citation Analysis]
464 Pavenski K, Hare GM, Mazer CD. Erythropoietic neuroprotection: Holy Grail or potential to fail? Intensive Care Med 2011;37:1403-5. [PMID: 21779850 DOI: 10.1007/s00134-011-2305-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
465 Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Brookhart MA. The comparative short-term effectiveness of iron dosing and formulations in US hemodialysis patients. Am J Med 2013;126:541.e1-541.e14. [PMID: 23597800 DOI: 10.1016/j.amjmed.2012.11.030] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
466 Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med 2012;31:2973-84. [PMID: 22711298 DOI: 10.1002/sim.5403] [Cited by in Crossref: 247] [Cited by in F6Publishing: 216] [Article Influence: 24.7] [Reference Citation Analysis]
467 Bernieh B, Abouchacra S, Boobes Y, Al Hakim MR, Nagelkerke N, Chaaban A, Ahmed M, Hussain Q, Jack HE, Abayechi F, Khan I, Gebran N. Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome. Int Urol Nephrol 2014;46:453-9. [PMID: 24448756 DOI: 10.1007/s11255-013-0640-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
468 Vilayur E, Harris DC. Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol 2009;5:375-83. [PMID: 19455178 DOI: 10.1038/nrneph.2009.76] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
469 Hayat A, Haria D, Salifu MO. Erythropoietin stimulating agents in the management of anemia of chronic kidney disease. Patient Prefer Adherence 2008;2:195-200. [PMID: 19920963 DOI: 10.2147/ppa.s2356] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 0.4] [Reference Citation Analysis]
470 Zarychanski R, Turgeon AF, McIntyre L, Fergusson DA. Erythropoietin-receptor agonists in critically ill patients: a meta-analysis of randomized controlled trials. CMAJ 2007;177:725-34. [PMID: 17823140 DOI: 10.1503/cmaj.071055] [Cited by in Crossref: 73] [Cited by in F6Publishing: 66] [Article Influence: 4.9] [Reference Citation Analysis]
471 Watnick S, Stooksbury M, Winter R, Riscoe M, Cohen DM. White thrombus formation in blood tubing lines in a chronic hemodialysis unit. Clin J Am Soc Nephrol 2008;3:382-6. [PMID: 18184880 DOI: 10.2215/CJN.03540807] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
472 Bennett CL, Hoque S, Olivieri N, Taylor MA, Aboulafia D, Lubaczewski C, Bennett AC, Vemula J, Schooley B, Witherspoon BJ, Godwin AC, Ray PS, Yarnold PR, Ausdenmoore HC, Fishman M, Herring G, Ventrone A, Aldaco J, Hrushesky WJ, Restaino J, Thomsen HS, Yarnold PR, Marx R, Migliorati C, Ruggiero S, Nabhan C, Carson KR, McKoy JM, Yang YT, Schoen MW, Knopf K, Martin L, Sartor O, Rosen S, Smith WK. Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997-2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR). EClinicalMedicine 2021;31:100693. [PMID: 33554084 DOI: 10.1016/j.eclinm.2020.100693] [Reference Citation Analysis]
473 Coyne DW. The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial. Kidney Int 2012;82:235-41. [PMID: 22437411 DOI: 10.1038/ki.2012.76] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 5.7] [Reference Citation Analysis]
474 Cappellini MD, Comin-Colet J, de Francisco A, Dignass A, Doehner W, Lam CS, Macdougall IC, Rogler G, Camaschella C, Kadir R, Kassebaum NJ, Spahn DR, Taher AT, Musallam KM; IRON CORE Group. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol 2017;92:1068-78. [PMID: 28612425 DOI: 10.1002/ajh.24820] [Cited by in Crossref: 137] [Cited by in F6Publishing: 111] [Article Influence: 27.4] [Reference Citation Analysis]
475 Ibrahim HN, Foley RN, Zhang R, Gilbertson DT, Collins AJ. Parenteral iron use: possible contribution to exceeding target hemoglobin in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:623-9. [PMID: 19211669 DOI: 10.2215/CJN.03850808] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
476 Choukroun G, Kamar N, Dussol B, Etienne I, Cassuto-Viguier E, Toupance O, Glowacki F, Moulin B, Lebranchu Y, Touchard G. Correction of postkidney transplant anemia reduces progression of allograft nephropathy. J Am Soc Nephrol. 2012;23:360-368. [PMID: 22193388 DOI: 10.1681/asn.2011060546] [Cited by in Crossref: 68] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
477 Briet M, Barhoumi T, Mian MO, Sierra C, Boutouyrie P, Davidman M, Bercovitch D, Nessim SJ, Frisch G, Paradis P, Lipman ML, Schiffrin EL. Effects of recombinant human erythropoietin on resistance artery endothelial function in stage 4 chronic kidney disease. J Am Heart Assoc 2013;2:e000128. [PMID: 23584809 DOI: 10.1161/JAHA.113.000128] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
478 Tonelli M, Hemmelgarn B, Reiman T, Manns B, Reaume MN, Lloyd A, Wiebe N, Klarenbach S. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009;180:E62-71. [PMID: 19407261 DOI: 10.1503/cmaj.090470] [Cited by in Crossref: 130] [Cited by in F6Publishing: 109] [Article Influence: 10.0] [Reference Citation Analysis]
479 Cody JD, Hodson EM. Recombinant human erythropoietin versus placebo or no treatment for the anaemia of chronic kidney disease in people not requiring dialysis. Cochrane Database Syst Rev 2016;:CD003266. [PMID: 26790135 DOI: 10.1002/14651858.CD003266.pub3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
480 Maurin N. [The role of platelets in atherosclerosis, diabetes mellitus, and chronic kidney disease. An attempt at explaining the TREAT study results]. Med Klin (Munich) 2010;105:339-44. [PMID: 20503008 DOI: 10.1007/s00063-010-1062-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
481 Drüeke TB, Massy ZA. Erythropoiesis-Stimulating Agents and Mortality. J Am Soc Nephrol 2019;30:907-8. [PMID: 31015256 DOI: 10.1681/ASN.2019030266] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
482 Hanafusa N, Nomura T, Hasegawa T, Nangaku M. Age and anemia management: relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patients. Nephrol Dial Transplant 2014;29:2316-26. [PMID: 25150218 DOI: 10.1093/ndt/gfu272] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
483 Li X, Kshirsagar AV, Brookhart MA. Safety of intravenous iron in hemodialysis patients. Hemodial Int 2017;21 Suppl 1:S93-S103. [PMID: 28370957 DOI: 10.1111/hdi.12558] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
484 Tangri N, Miskulin DC, Zhou J, Bandeen-Roche K, Michels WM, Ephraim PL, McDermott A, Crews DC, Scialla JJ, Sozio SM, Shafi T, Jaar BG, Meyer K, Boulware LE; DEcIDE Network Patient Outcomes in End-Stage Renal Disease Study Investigators. Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study. Nephrol Dial Transplant 2015;30:667-75. [PMID: 25366328 DOI: 10.1093/ndt/gfu349] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
485 Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014;:CD010590. [PMID: 25486075 DOI: 10.1002/14651858.CD010590.pub2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
486 Fukuhara S, Akizawa T, Morita S, Tsubakihara Y. Understanding measurements of vitality in patients with chronic kidney disease: connecting a quality-of-life scale to daily activities. PLoS One 2012;7:e40455. [PMID: 22808164 DOI: 10.1371/journal.pone.0040455] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
487 Mirinejad H, Gaweda AE, Brier ME, Zurada JM, Inanc T. Individualized drug dosing using RBF-Galerkin method: Case of anemia management in chronic kidney disease. Comput Methods Programs Biomed 2017;148:45-53. [PMID: 28774438 DOI: 10.1016/j.cmpb.2017.06.008] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
488 Noonan ML, Ni P, Agoro R, Sacks SA, Swallow EA, Wheeler JA, Clinkenbeard EL, Capitano ML, Prideaux M, Atkins GJ, Thompson WR, Allen MR, Broxmeyer HE, White KE. The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model. J Bone Miner Res 2021;36:1117-30. [PMID: 33592127 DOI: 10.1002/jbmr.4272] [Reference Citation Analysis]
489 Sagheb MM, Fallahzadeh MA, Moaref A, Fallahzadeh MH, Dormanesh B. Comparison of Hemoglobin Levels Before and After Hemodialysis and Their Effects on Erythropoietin Dosing and Cost. Nephrourol Mon 2016;8:e38495. [PMID: 27713870 DOI: 10.5812/numonthly.38495] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
490 Seliger S, Fox KM, Gandra SR, Bradbury B, Hsu VD, Walker L, Chiou CF, Fink JC. Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study. Clin J Am Soc Nephrol. 2010;5:882-888. [PMID: 20299377 DOI: 10.2215/cjn.07171009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
491 Sanghani NS, Haase VH. Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience. Adv Chronic Kidney Dis 2019;26:253-66. [PMID: 31477256 DOI: 10.1053/j.ackd.2019.04.004] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 31.5] [Reference Citation Analysis]